Adynxx (ADYX) 10-K 24 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 20, 2014	Jun. 28, 2013
Document Information [Line Items]	'	'	'
Entity Registrant Name	'Alliqua, Inc.	'	'
Entity Central Index Key	'0001054274	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Trading Symbol	'ALQA	'	'
Entity Common Stock, Shares Outstanding	'	12,501,525	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$18,146,801

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets:	'	'
Cash and cash equivalents	$12,100,544	$260,357
Accounts receivable	156,831	108,866
Inventory	501,469	319,326
Prepaid expenses and other current assets	88,390	193,647
Total current assets	12,847,234	882,196
Improvements and equipment, net	1,745,248	1,915,179
Intangible assets, net	2,258,477	10,329,167
Goodwill	425,969	425,969
Other assets	174,640	174,640
Total assets	17,451,568	13,727,151
Current Liabilities:	'	'
Accounts payable	746,609	572,635
Accrued expenses	1,267,899	249,728
Payable for distribution rights	333,333	0
Deferred revenue	39,000	39,000
Warrant liability	933,465	605,737
Deferred lease incentive liability - current	8,337	0
Other current liabilities	24,821	65,397
Total current liabilities	3,353,464	1,532,497
Deferred lease incentive liability	92,408	0
Deferred tax obligation	53,000	44,000
Total liabilities	3,498,872	1,576,497
Commitments and Contingencies	'	'
Stockholders' Equity	'	'
Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock, par value $0.001 per share, 45,714,286 shares authorized; 11,484,191 and 5,924,627 shares issued and outstanding as of December 31, 2013 and December 31, 2012, respectively	11,484	5,925
Additional paid-in capital	58,538,491	34,785,126
Subscription receivable	0	-20,000
Accumulated deficit	-44,597,279	-22,620,397
Total stockholders' equity	13,952,696	12,150,654
Total liabilities and stockholders' equity	$17,451,568	$13,727,151

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Dec. 31, 2013	Dec. 31, 2012
Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00
Preferred Stock, Shares Authorized	1,000,000	1,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	45,714,286	45,714,286
Common Stock, Shares, Issued	11,484,191	5,924,627
Common Stock, Shares, Outstanding	11,484,191	5,924,627

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenue, net of returns, allowances and discounts	$1,797,745	$1,228,674
Cost of revenues	2,097,033	1,837,169
Gross loss	-299,288	-608,495
Operating expenses	'	'
Selling, general and administrative, (inclusive of stock-based compensation compensation of $5,513,861 and $1,975,115 for the years ended December 31, 2013 and 2012 - see Note 10)	11,669,998	4,054,373
Research and product development	63,204	233,819
Impairment of in-process research and development	8,100,000	0
Total operating expenses	19,833,202	4,288,192
Loss from operations	-20,132,490	-4,896,687
Other income (expense)	'	'
Interest expense	-4,807	-3,353
Other income	0	4,888
Interest income	2,913	817
Change in value of warrant liability	-1,833,498	0
Total other (expense) income	-1,835,392	2,352
Income tax provision	9,000	11,000
Net loss	-21,976,882	-4,905,335
Deemed dividend to preferred stockholders	-462,006	0
Net loss attributable to common stockholders	($22,438,888)	($4,905,335)
Basic and diluted net loss per common share (in dollars per share)	($3.14)	($0.91)
Weighted average shares used in computing basic and diluted net loss per common share (in shares)	7,140,613	5,383,995

Consolidated_Statements_of_Ope1

Consolidated Statements of Operations [Parenthetical] (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Allocated Share-based Compensation Expense	$5,513,861	$1,975,115

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Redeemable Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Subscription Receivable [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2011	$13,634,086	$0	$4,779	$31,344,369	$0	($17,715,062)
Balance (in shares) at Dec. 31, 2011	'	0	4,778,831	'	'	'
Issuance of common stock for cash, net of issuance costs	1,446,788	0	988	1,465,800	-20,000	0
Issuance of common stock for cash, net of issuance costs (in shares)	'	0	987,429	'	'	'
Preferred stock contingent beneficial conversion feature triggered due to price reset provision	0	'	'	'	'	'
Issuance of common stock for services	250,000	0	57	249,943	0	0
Issuance of common stock for services (in shares)	'	0	57,143	'	'	'
Issuance of common stock to related party for services	300,000	0	101	299,899	0	0
Issuance of common stock to related party for services (in shares)	'	0	101,224	'	'	'
Stock-based compensation	1,425,115	0	0	1,425,115	0	0
Net loss	-4,905,335	0	0	0	0	-4,905,335
Balance at Dec. 31, 2012	12,150,654	0	5,925	34,785,126	-20,000	-22,620,397
Balance (in shares) at Dec. 31, 2012	'	0	5,924,627	'	'	'
Issuance of common stock for cash, net of issuance costs	15,777,293	0	4,599	15,772,694	0	0
Issuance of common stock for cash, net of issuance costs (in shares)	'	0	4,599,334	'	'	'
Issuance of preferred stock for cash, net of cash issuance costs of $70,000, warrant issuance costs of $43,906 and $369,903 discount attributable to warrant and beneficial conversion feature	413,809	516,191	0	413,809	0	0
Issuance of preferred stock for cash, net of cash issuance costs of $70,000, warrant issuance costs of $43,906 and $369,903 discount attributable to warrant and beneficial conversion feature (in shares)	'	250,000	0	'	'	'
Preferred stock contingent beneficial conversion feature triggered due to price reset provision	89,379	-89,379	0	89,379	0	0
Accretion of discount as deemed dividend on preferred stock	-462,006	462,006	0	-462,006	0	0
Conversion of preferred stock into common stock	888,818	-888,818	280	888,538	0	0
Conversion of preferred stock into common stock (in shares)	'	-250,000	279,505	'	'	'
Issuance of common stock for services	87,379	0	26	87,353	0	0
Issuance of common stock for services (in shares)	'	0	26,264	'	'	'
Issuance of common stock to related party for services	1,221,708	0	372	1,221,336	0	0
Issuance of common stock to related party for services (in shares)	'	0	372,330	'	'	'
Exercise of warrants	0	0	261	-261	0	0
Exercise of warrants (in shares)	'	0	261,030	'	'	'
Extinguishment of warrant liability	1,505,770	0	0	1,505,770	0	0
Receipt of subscription receivable	20,000	0	0	0	20,000	0
Stock-based compensation, net of shares withheld for employee taxes	4,204,774	0	21	4,204,753	0	0
Stock-based compensation, net of shares withheld for employee taxes (in shares)	'	0	21,101	'	'	'
Fair value of rent provided by related party	32,000	0	0	32,000	0	0
Net loss	-21,976,882	0	0	0	0	-21,976,882
Balance at Dec. 31, 2013	$13,952,696	$0	$11,484	$58,538,491	$0	($44,597,279)
Balance (in shares) at Dec. 31, 2013	'	0	11,484,191	'	'	'

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity [Parenthetical] (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Payments of Stock Issuance Costs	$680,132	$87,475
Stock Issuance Costs	70,000	'
Warrant Issuance Costs	43,906	'
Discount Attributable To Warrant	369,903	'
Derivative Liability, Current	$933,465	$605,737
Shares Withheld For Employee Taxes	14,299	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash Flows From Operating Activities	'	'
Net loss	($21,976,882)	($4,905,335)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	674,225	647,818
Amortization of deferred lease incentive	-695	0
Deferred income taxes	9,000	11,000
Provision for inventory obsolescence	58,930	17,650
Loss on disposal of property and equipment	19,236	0
Stock-based compensation expense	4,204,774	1,425,115
Impairment of in process research and development	8,100,000	0
Stock issued for services rendered	87,379	250,000
Stock issued for services rendered by related parties	1,221,708	300,000
Change in value of warrant liability	1,833,498	0
Fair value of rent provided by related party	32,000	0
Changes in operating assets and liabilities:	'	'
Accounts receivable	-47,965	-41,093
Inventory	-241,073	-106,686
Prepaid expenses and other current assets	105,257	-133,311
Accounts payable	173,974	320,883
Accrued expenses and other current liabilities	977,595	208,866
Deferred revenue	0	39,000
Net Cash Used in Operating Activities	-4,769,039	-1,966,093
Cash Flows From Investing Activities	'	'
Purchase of distribution rights	-66,667	0
Purchase of property and equipment	-51,400	-86,186
Net Cash Used by Investing Activities	-118,067	-86,186
Cash Flows From Financing Activities	'	'
Net proceeds from issuance of common stock	15,797,293	2,002,525
Net proceeds from issuance of preferred stock	930,000	0
Net proceeds from issuance of notes payable	0	50,000
Net Cash Provided by Financing Activities	16,727,293	2,052,525
Net Increase in Cash and Cash Equivalents	11,840,187	246
Cash and Cash Equivalents - Beginning of year	260,357	260,111
Cash and Cash Equivalents - End of year	12,100,544	260,357
Supplemental Disclosure of Cash Flows Information	'	'
Interest	4,808	3,353
Non-cash investing and financing activities	'	'
Cashless warrant exercise	1,505,770	0
Leasehold improvements provided by landlord	101,440	0
Conversion of note payable to equity	0	50,000
Warrant issued to placement agent in connection with preferred stock	43,906	0
Warrant and beneficial conversion feature issued to investor as discount in connection with preferred stock	369,903	0
Preferred stock contingent beneficial conversion feature triggered due to price reset provision	89,379	0
Deemed dividend on preferred stock	462,006	0
Conversion of preferred stock into common stock	$888,818	$0

Description_of_Business_and_Ba

Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
		1	Description of Business and Basis of Presentation
	Alliqua, Inc. (the “Company”) is a provider of advanced wound care solutions. The Company’s primary business strategy is to create superior outcomes for patients, providers, and partners through its hydrogel technology platform and licensed and proprietary products.  Core businesses include advanced wound care and contract manufacturing. The Company seeks to leverage its proprietary hydrogel and licensed technology platform to add value to its own products and those of its partners.
	Principles of Consolidation
	The accompanying consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries, AquaMed Technologies, Inc., HepaLife Biosystems, Inc. and Alliqua Biomedical, Inc.  All significant inter-company transactions and accounts have been eliminated in consolidation.
	Reclassifications
	Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.
	Reverse Stock Split
	The Company effected a 1-for-43.75 reverse stock split of its outstanding common stock on November 18, 2013. The accompanying consolidated financial statements and accompanying notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock retained a par value of $0.001 per share. Accordingly, stockholders’ equity reflects the reverse stock split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the reverse stock split.

Liquidity

Liquidity	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Liquidity Disclosure Note [Text Block]	'
		2	Liquidity
	The Company has experienced negative operating cash flows since inception and has funded its operations primarily from sales of common stock and other securities. The Company’s cash requirements have historically been for product development, clinical trials, marketing and sales activities, finance and administrative costs, capital expenditures and overall working capital.
	During the year ended December 31, 2013, the Company sold 4,599,334 shares of common stock for total net proceeds of $15,797,293, and 250,000 shares of preferred stock for total net proceeds of $930,000 as detailed in Note 10 – Stockholders’ Equity. The Company has revamped strategies to focus on being a provider of wound care solutions as well as continue to be a contract manufacturer. The use of proceeds of the 2013 financings will largely be used to support the sales and marketing of wound care solutions.
	In 2013, the Company restructured its senior management team with the goal of maximizing the potential for success in achieving sales and marketing goals. In addition to appointing a new chief executive officer and chief financial officer, the Company has also hired a number of senior sales and marketing executives and professionals. The Company expects to continue to attend trade shows and seek other avenues to market its products.  During 2013, the Company also established an independent network of agents to sell wound care products as well as an extensive channel reach through a network of distributors.
	The implementation of the growth strategy will continue to result in an increase in the Company’s fixed cost structure. Due to the time delay between outlays for working capital expenditures such as costs to acquire rights to additional products, the hiring and training of sales agents and personnel, pre-launch marketing costs, the purchasing of inventory, and the billing and collection of revenue, the Company expects to record an increase in net operating cash outflows from operations for the first half of 2014 as compared to the last half of 2013.
	Based on the factors above, the Company believes that cash on hand and cash generated from operations will be sufficient to fund the business for the next 12 months. However, future results of operations involve significant risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, potential demand for the Company’s products, risks from its competition, regulatory approval of new products, technological change, and dependence on key personnel.
	In order to complete the Company’s future growth strategy additional equity and/or debt financing will be required. If unable to raise additional capital or if the Company encounters circumstances that place unforeseen constraints on capital resources, it will be required to take even stronger measures to conserve liquidity, which may include, but are not limited to, eliminating all non-essential positions and ceasing all marketing efforts. The Company would have to curtail business development activities and suspend the pursuit of the Company’s business plan. There can be no assurance that the Company will be successful in improving revenues, reducing expenses and/or securing additional capital in sufficient amounts and on favorable terms.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
		3	Summary of Significant Accounting Policies
	Use of Estimates in the Financial Statements
	The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes.   These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, account receivable reserves, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles and goodwill. Actual results could differ from the estimates.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. The Company’s balance of cash and cash equivalents at December 31, 2013 and 2012 consisted principally of bank deposits.  From time to time, the Company’s cash account balances may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation guarantee limit.   The Company reduces its exposure to credit risk by maintaining its cash deposits with major financial institutions and monitoring their credit ratings.
	Accounts Receivable
	Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms.  The Company’s accounts receivable balance is a result of product sales and contract manufacturing.  These receivables have historically been paid timely.  Due to the nature of the accounts receivable balance, the Company believes there is no significant risk of collection.  If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, allowances for doubtful accounts would be required.
	Inventory
	Inventory is valued at the lower of cost or market on a first-in, first-out basis. Reserves for inventory obsolescence are based on expiration date and are utilized to account for slow-moving inventory.   At December 31, 2013 and 2012, the Company had reserves for obsolete inventory of $76,580 and $17,650, respectively.
	Improvements and Equipment
	Improvements and equipment are recorded at cost. Depreciation of equipment is computed utilizing the straight-line method over the estimated useful lives of the assets. Amortization of leasehold improvements is computed utilizing the straight-line method over the shorter of the remaining lease term or estimated useful life. Repairs and maintenance costs are expensed as incurred. Additions and betterments are capitalized.
	Acquired In-Process Research and Development
	In-process research and development (“IPR&D”) represents the fair value assigned to incomplete research projects that the Company acquires through business combinations which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&D are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. The Company tests IPR&D for impairment at least annually or more frequently if impairment indicators exist.
	Goodwill and Other Intangible Assets
	The Company accounts for goodwill and intangible assets in accordance with the accounting guidance which requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value.  Goodwill of $425,969 was assigned during the acquisition of Hydrogel Design Systems by AquaMed Technologies, Inc. in 2009.   The Accounting Standards Codification (“Codification”) requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment). Application of the goodwill impairment test requires judgment, including the identification of reporting units, assigning assets and liabilities to reporting units, assigning goodwill to reporting units, and determining the fair value. Significant judgment is required to estimate the fair value of reporting units which includes estimating future cash flows, determining appropriate discount rates and other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value and/or goodwill impairment.
	When testing goodwill for impairment, the Company may assess qualitative factors for some or all of its reporting units to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount, including goodwill. Alternatively, the Company may bypass this qualitative assessment for some or all of our reporting units and perform a detailed quantitative test of impairment (step 1). If the Company performs the detailed quantitative impairment test and the carrying amount of the reporting unit exceeds its fair value, the Company would perform an analysis (step 2) to measure such impairment. In 2013, the Company first performed a qualitative assessment to identify and evaluate events and circumstances to conclude whether it is more likely than not that the fair value of the Company’s reporting unit is less than its carrying amount. Based on the Company’s qualitative assessments, the Company concluded that a positive assertion can be made from the qualitative assessment that it is not more likely than not that the fair value of the reporting unit is less than its carrying amount.  In accordance with the Codification, the Company reviews the carrying value of its intangibles and other long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the asset or asset group to the undiscounted cash flows that the asset or asset group is expected to generate. If the undiscounted cash flows of such assets are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group, if any, exceeds its fair market value. No impairment was deemed to exist as of December 31, 2013.
	Impairment of Long-Lived Assets Subject to Amortization
	The Company amortizes intangible assets with finite lives over their estimated useful lives and reviews them for impairment annually or whenever an impairment exists.  The Company continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. As of December 31, 2013, Company management believed that no revision to the remaining useful lives or write-down of the Company’s long-lived assets was required, and similarly, no such revisions were required for the year ended December 31, 2012.
	Fair Value of Financial Instruments
	The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments.
	Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows:
	Level 1: Observable prices in active markets for identical assets and liabilities.
	Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities.
	Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
	Revenue Recognition
	Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred; title and risk of loss have passed to the customer, there is a fixed or determinable sales price, and collectability of that sales price is reasonably assured.  Deposits received on product orders are recorded as deferred revenue until revenues are earned when the products are shipped to customers.  For irradiation services, the Company records revenue based upon an hourly service charge as services are provided.
	Research and Development
	Research and development expenses represent costs incurred to develop technology. Research and development expenses are charged to operations as they are incurred, including internal costs, costs paid to sponsoring organizations, and contract services for any third party laboratory work. Research and development expenses are tracked by project.  As of December 31, 2013 and 2012 research and development costs totaled $63,204 and $233,819, respectively.
	Cost of Goods Sold and Selling, General and Administrative Expenses
	Costs associated with the production and procurement of product are included in cost of goods sold, including shipping and handling costs such as inbound freight costs, purchasing and receiving costs, inspection costs and other product procurement related charges. All other expenses, excluding interest and income taxes, are included in selling, general and administrative expenses, as the predominant expenses associated therewith are general and administrative in nature.
	Advertising Expenses
	Advertising and marketing costs are expensed as incurred. Advertising expenses for the years ended December 31, 2013 and 2012 were $298,859 and $139,024, respectively.
	Shipping and Handling
	Shipping and handling costs are paid for by the Company. Shipping and handling costs amounted to approximately $23,523 and $14,635 as of December 31, 2013 and 2012, respectively, and are included in selling, general and administrative expenses.
	Income Taxes
	The Company accounts for income taxes pursuant to the asset and liability method which requires deferred tax assets and liabilities to be recognized for the expected future tax consequences attributable to temporary differences between the financial statement carrying amounts and their respective tax bases of assets and liabilities.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period enacted. A valuation allowance is provided when it is more likely than not that a portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible.
	The Company adopted the provisions of Accounting Standards Codification Topic 740 (“ASC 740”) related to the accounting for uncertainty in income taxes recognized in an enterprise's consolidated financial statements. ASC 740 prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns.
	The benefit of tax positions taken or expected to be taken in the Company's income tax returns are recognized in the financial statements if such positions are more likely than not of being sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits”. A liability is recognized (or amount of net operating loss carryover or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. Interest costs and related penalties related to unrecognized tax benefits are required to be calculated, if applicable. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as selling, general and administrative expenses. No interest or penalties were recorded during the years ended December 31, 2013 and 2012. As of December 31, 2013 and December 31, 2012, no liability for unrecognized tax benefits was required to be reported. The Company files tax returns in U.S. federal, state and local jurisdictions, including Pennsylvania, and has tax returns subject to examination by tax authorities beginning in the year ended December 31, 2010. The Company does not expect any significant changes in its unrecognized tax benefits in the next year.
	Common Stock Purchase Warrants
	The Company assesses classification of common stock purchase warrants at each reporting date to determine whether a change in classification between assets and liabilities or equity is required.  The Company’s free standing derivatives consist of warrants to purchase common stock that were issued pursuant to a Securities Purchase Agreement on November 8, 2012.  The Company evaluated the common stock purchase warrants to assess their proper classification in the consolidated balance sheet and determined that the common stock purchase warrants contain exercise reset provisions.  Accordingly, these instruments have been classified as warrant liabilities in the accompanying consolidated balance sheets as of December 31, 2013 and 2012.  The Company re-measures warrant liabilities at each reporting and exercise date, with changes in fair value recognized in earnings for each reporting period.
	Stock-Based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on interim financial reporting dates and vesting dates until the service period is complete. The fair value amount is then recognized over the period services are required to be provided in exchange for the award, usually the vesting period. The Company recognizes stock-based compensation expense on a graded-vesting basis over the requisite service period for each separately vesting tranche of each award. Stock-based compensation expense is reflected within operating expenses in the consolidated statements of operations. The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment.
	Net Loss Per Common Share
	Basic net loss per common share is computed based on the weighted average number of shares of common stock outstanding during the periods presented. Common stock equivalents, consisting of warrants, stock options and non-vested restricted stock units (“RSUs”), were not included in the calculation of the diluted loss per share because their inclusion would have been anti-dilutive.
	The total common shares issuable upon the exercise of stock options, warrants and non-vested restricted stock units are as follows:
			December 31,
			2013	2012
	Stock Options		4,985,586	2,333,822
	Warrants		3,822,557	1,004,208
	Non-Vested Restricted Stock Units		35,376	70,753
	Total		8,843,519	3,408,783

Inventory

Inventory	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
		4	Inventory
	Inventory consists of the following:
			December 31,
			2013		2012
	Raw materials		$	174,176	$	209,820
	Work in process			57,030		25,119
	Finished goods			346,843		102,037
	Less: Inventory reserve			-76,580		-17,650
	Total		$	501,469	$	319,326

Improvements_and_Equipment_net

Improvements and Equipment, net	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
		5	Improvements and Equipment, net
	Improvements and equipment consist of the following:
				December 31,
			Useful Life	2013		2012
			(Years)
	Machinery and equipment		10	$	2,869,453	$	2,869,453
	Office furniture and equipment		10		44,844		40,124
	Leasehold improvements		(A)		228,021		108,139
					3,142,318		3,017,716
	Less: Accumulated depreciation and amortization				-1,397,070		-1,102,537
	Improvements and equipment, net			$	1,745,248	$	1,915,179
	(A) Leasehold improvements are amortized over the shorter of the remaining lease term or estimated useful life.
	Depreciation and amortization expense was $303,535 and $297,818 for the years ended December 31, 2013 and 2012, respectively.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Accrued Liabilities, Current [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
		6	Accrued Expenses
	Accrued expenses consist of the following:
			December 31,
			2013		2012
	Salaries, benefits and incentive compensation		$	1,036,771	$	230,281
	Professional fees			83,317		11,736
	Inventory			127,786		-
	Other			20,025		7,711
	Total accrued expenses		$	1,267,899	$	249,728

Intangible_Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
		7	Intangible Assets
	Intangible Assets
	During the fourth quarter of 2013 the Company tested the in-process research and development, also referred to as the Company’s HepaMate artificial liver technology acquired as part of the 2010 merger with AquaMed, for impairment.  Prior to the impairment analysis, the value of the IPR&D remained at the fair value assigned at acquisition of $8,100,000. At acquisition, the project had not reached technological feasibility.  The Company has not allocated any resources to the HepaMate technology since the merger other than the fees associated with the maintenance of patents and intellectual property related to the technology.  No plans have been made to renew the clinical trials.  The Company currently estimates a significant expense over a 5 year period is needed to complete the remainder of the clinical trial process.
	The strategy of the Company has evolved to become a provider of advanced wound care products through the sale of its proprietary products and technologies acquired through in-licensing and acquisition.  The Company does not intend to further develop the HepaMate technology.  In 2013 the Company engaged an investment bank to find a strategic partner for the HepaMate technology however this process has been unsuccessful.  Given the change in management as discussed and the refocus of efforts, management does not intend to allocate any new capital towards the development activities of this technology.  Management has also considered the marketability and valuation considerations of the technology and has concluded the fair value of the technology to have limited commercial recoverability.  As a result of these evaluations, the Company recognized an impairment of IPR&D of $8,100,000 during the year ended December 31, 2013.The evaluation of amounts recoverable in connection with intangible assets is a process that requires considerable exercise of judgment. Had different estimates and assumptions been used in this process, the measured impairments may have been different.  The Company will continue to pursue strategies to optimize the value of the HepaMate technology.
	The Company reviewed its other intangible definite-lived assets and did not identify any other impairment as of December 31, 2013.
	The gross carrying amount and accumulated amortization of intangible assets as of December 31, 2013 and 2012 are as follows:
					December 31,
					2013
											Net
			Useful Life		Gross		Accumulated				Carrying
			(Years)		Amount		Amortization		Impairment		Amount
	In process research and development				$	8,100,000	$	-	$	-8,100,000	$	-
	Technology		10			3,000,000		-1,475,000		-		1,525,000
	Customer relationships		12			600,000		-245,834		-		354,166
	Distribution rights		5.27			400,000		-20,689		-		379,311
					$	12,100,000	$	-1,741,523	$	-8,100,000	$	2,258,477
					December 31,
					2012
											Net
			Useful Life		Gross		Accumulated				Carrying
			(Years)		Amount		Amortization		Impairment		Amount
	In process research and development				$	8,100,000	$	-	$	-	$	8,100,000
	Technology		10			3,000,000		-1,175,000		-		1,825,000
	Customer relationships		12			600,000		-195,833		-		404,167
					$	11,700,000	$	-1,370,833	$	-	$	10,329,167
	Amortization expense attributable to intangible assets for the years ended December 31, 2013 and 2012 was $370,690 and $350,000, respectively.
	Amortization expense in each of the five years and thereafter subsequent to December 31, 2013 related to the Company’s intangible assets is expected to be as follows:
			Expected
			Amortization
			Expense
	2014		$	426,190
	2015			426,190
	2016			426,190
	2017			426,190
	2018			424,548
	Thereafter			129,169
	Total		$	2,258,477

Operating_Leases

Operating Leases	12 Months Ended
	Dec. 31, 2013
Leases, Operating [Abstract]	'
Leases of Lessee Disclosure [Text Block]	'
		8	Operating Leases
	The Company has an obligation for its corporate offices and commercial manufacturing facility located at 2150 Cabot Boulevard West, Langhorne, Pennsylvania.   On July 24, 2013 the Company extended its lease for it operating facilities in Langhorne, PA for an additional period of 10 years commencing on February 1, 2016 and continuing through and including January 31, 2026. Under the extended lease, the landlord agreed to make certain improvements to the facility. For tenant improvements funded by the landlord, the Company recorded a deferred lease incentive liability in accrued and other long-term liabilities on the consolidated balance sheet and amortizes the deferred liability as a reduction to rent expense on the consolidated statement of operations over the term of the lease. At December 31, 2013, the deferred lease incentive liability was $100,745.
	Total rent expense was $204,930 and $191,597 for the years ended December 31, 2013 and 2012, respectively.
	Future minimum lease payments, excluding expense reimbursements, under noncancelable operating leases in each of the five years and thereafter subsequent to December 31, 2013 are as follows:
	2014		$	204,689
	2015			206,250
	2016			207,309
	2017			207,405
	2018			207,405
	Thereafter			1,469,119
	Total		$	2,502,177
	The Company previously had an agreement for shared corporate office space located at 850 3rd Avenue, New York, NY. This agreement was modified in January 2012, such that, the Company issued a related party 45,714 shares of common stock as consideration for an extension of the lease agreement until December 31, 2012 and, effective as of December 31, 2011, the elimination of the requirement to make any further cash payments. At the date of issuance, the common stock was valued at $100,000 and the associated expense was amortized over the term of the lease.   The Company did not have any right to extend the terms of the lease agreement past December 31, 2012. As the Company was in the process of moving its corporate headquarters to its Langhorne, PA facility, it was authorized to occupy this space through June 30, 2013 at no additional cost. As such, the Company recognized the fair value of the rent of $32,000 in the year ended December 31, 2013.  Total rent expense for this space amounted to $86,000 for the year ended December 31, 2012.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
		9	Commitments and Contingencies
	Employment Agreements for Former Employees
	On May 16, 2012, the Company entered into a three year executive employee agreement with its former president and former Board member retroactive to January 1, 2012. The agreement provided for an annual salary of $200,000 in 2012, $225,000 in 2013 and $250,000 in 2014, payable in a combination of cash and shares of common stock. An option to purchase 125,714 shares of common stock, at an exercise price of $8.75 per share, was granted and was scheduled to vest one third each year on the first, second and third anniversary of the date of grant and had a term of ten years. In addition, stock options to purchase 68,571 shares of common stock previously awarded were accelerated to vest and became exercisable on the date of execution of the employment agreement. On November 27, 2012, the executive resigned from his position as president, but remained a member of the Board. On June 28, 2013, the Company entered into a separation and general release agreement with this executive, pursuant to which the employment agreement was terminated effective as of December 31, 2012; non-competition and non-solicitation obligations under the employment agreement remain.  All unvested options were immediately vested in full. The Company also entered into a consulting agreement on June 28, 2013, retroactively effective to January 1, 2013, pursuant to which, this former executive will provide consulting services in exchange for (i) a one-time grant of 186,165 shares of common stock, and (ii) monthly payments of $2,500 from June 2013 through June 2014. The value of the shares issued were $570,130 and are included in stock-based compensation. See Note 10 – Stockholders’ Equity.
	On May 31, 2012, the Company entered into a three year executive employee agreement with its former executive chairman and a current Board member retroactive to January 1, 2012. The agreement provided for an annual salary of $200,000 in 2012, $225,000 in 2013 and $250,000 in 2014, payable in a combination of cash and shares of common stock. An option to purchase 125,714 shares of common stock, at an exercise price of $8.75 per share, was granted and scheduled to vest one third each year on the first, second and third anniversary of the date of grant and had a term of ten years. In addition, stock options to purchase 68,571 shares of common stock previously awarded were accelerated to vest and became exercisable on the date of execution of the employment agreement. On November 27, 2012, the executive resigned from his position as executive chairman, but remained a member of the Board. On November 11, 2013, the Company entered into a separation and general release agreement with this executive, pursuant to which the employment agreement was terminated effective as of December 31, 2012; non-competition and non-solicitation obligations under the employment agreement remain.  All unvested options were immediately vested in full. The Company also entered into a consulting agreement on November 11, 2013, retroactively effective to January 1, 2013 pursuant to which, this former executive will provide consulting services in exchange for (i) a one-time grant of 186,165 shares of common stock, and (ii) monthly payments of $2,500 from June 2013 through March 2014. The value of the shares issued were $651,578 and are included in stock-based compensation. See Note 10 – Stockholders’ Equity.
	Concurrently with the appointment of a new chief financial officer, the former chief financial officer, who also served as secretary and treasurer of the Company, resigned.  He remained with the Company through the end of 2013 as vice president of operations to assist with the transition, in accordance with a Transition Agreement and Release dated September 3, 2013. The Company granted an award of nonqualified stock options to purchase 114,286 shares of common stock at an exercise price of $4.38, which vested immediately upon the execution of a release on such date.  The options have a term of three years.  In addition, options held  under the following grants shall remain outstanding and exercisable: (i) incentive stock option granted December 9, 2010 with respect to 22,857 shares of the Company’s common stock granted pursuant to the HepaLife Technologies, Inc. 2001 Incentive Stock Option Plan; (ii)  nonqualified stock option agreement dated May 22, 2012 with respect to 22,857 shares of the Company’s common stock granted pursuant to the Alliqua, Inc. 2011 Long-Term Incentive Plan (the “2011 Plan”); and (iii)  nonqualified stock option granted November 27, 2012 with respect to 11,429 shares of the Company’s common stock granted pursuant to the 2011 Plan.  The Company has also agreed to pay him a monthly stipend of $600 per month during 2014.
	Consulting Agreements
	The Company currently has various consulting agreements for management consulting, marketing, public relations, investor relations and research and development. Some agreements are based on fixed fee arrangements and others on specified hourly rates.  The total fees included in operating expenses were $1,963,114 and $292,305 for years ended December 31, 2013 and 2012, respectively.  Included in this expense is stock-based compensation of $1,309,087 and $550,000 for the years ended December 31, 2013 and 2012, respectively.
	Cooperative and License Agreements
	On November 20, 2007, the Company exercised its license right under the CRADA by entering into an exclusive license agreement with the USDA, ARS for existing and future patents related to the PICM-19 hepatocyte cell lines. Under this license agreement, the Company is responsible for annual license maintenance fees commencing in 2010 for the term of the license, which is until the expiration of the last to expire licensed patents unless terminated earlier. The license agreement also requires certain milestone payments, if and when milestones are reached, as well as royalties on net sales of resulting licensed products, if any.
	On July 15, 2011, the Company, through its Alliqua Biomedical subsidiary, entered into a license agreement with Noble Fiber Technologies, LLC, whereby Alliqua has the exclusive right and license to manufacture and distribute “Silverseal Hydrogel Wound Dressings” and “Silverseal Hydrocolloid Wound Dressings”. The license is granted for ten years with an option to be extended for consecutive renewal periods of two years. An upfront license fee of $100,000 was expensed in 2011 as a selling, general and administrative expense. Royalties are to be paid equal to 9.75% of net sales of licensed products. The agreement calls for minimum royalties to be paid each calendar year as follows: 2013 - $200,000, 2014 - $400,000; 2015 - $500,000; and 2016 - $600,000. Total royalties charged to selling, general and administrative expense for the years ended December 31, 2013 and 2012 were $200,000 and 50,000, respectively. The remaining $192,987 royalty due for the year ended December 31, 2013, is included in accounts payable.
	Sorbion Distributor Agreement
	On September 23, 2013, Alliqua Biomedical entered into a distributor agreement (the “Sorbion Agreement”) with Sorbion GmbH & Co KG pursuant to which the Company became the exclusive distributor of sorbion sachet S, sorbion sana and new products with hydrokinetic fibers as primary dressings in the U.S. of America, Canada and Latin America, subject to certain exceptions.
	The initial term of the agreement ends on December 31, 2018 and will be extended for additional year terms until December 31, 2023, so long as the Company and Sorbion agree in September as to the minimum annual purchase amount for the calendar year that ends four years from the calendar year of such September.
	In order to maintain its exclusivity, the Company must purchase the following minimum amounts, in Euros, of the products for the indicated calendar year:
	Calendar Year		Minimum Annual Purchase Amount
	2014		500,000 Euros
	2015		1,000,000 Euros
	2016		2,500,000 Euros
	2017		4,000,000 Euros
	Since the Company must purchase the minimum amounts in Euros, the equivalent U.S. dollar expenditure will be subject to fluctuations in foreign currency exchange rates.
	The minimum annual purchase amounts in US. Dollars for each calendar year in the period from 2014-2017, based on the exchange rate as of December 31, 2013, are $689,000, $1,378,000, $3,444,000, and $5,510,000, respectively.
	If the Company fails to purchase products in amounts that meet or exceed the minimum annual purchase amount for a calendar year, it may cure such minimum purchase failure by paying Sorbion in cash an amount equal to the minimum annual purchase amount for such calendar year less the amount the Company paid to Sorbion for the products purchased for such calendar year.  If the Company does not cure a minimum purchase failure with a makeup payment for a calendar year, Sorbion may terminate the Company’s exclusivity with respect to the products and grant the Company non-exclusive rights with respect to the products.  If the Company does not cure a minimum purchase failure for two subsequent calendar years, Sorbion may terminate the agreement.  The Company will not be required to meet the minimal annual purchase amount if Sorbion fails to supply the Company with the products in accordance with the agreement.  Sorbion may also terminate the Company’s exclusivity with respect to the products if the Company does not cure a material breach of the agreement within 30 days.
	The Company has the right to use the trademarks related to the products. The Company will sell the products under their respective trademarked names and at prices determined by the Company.  Sorbion may determine in its sole discretion the prices of the products sold to the Company, which are subject to change beginning January 1, 2015. The Company will be eligible for certain discounts with respect to the purchase and shipping of the products if its orders of the products are above certain amounts.
	Carolon Distribution Rights Agreement
	In September 2013, the Company entered into an agreement with Carolon Company (“Carolon”) pursuant to which, the Company purchased the distribution rights to the sorbion sachet and sana products from Carolon.  The Company is committed to pay Carolon (i) an aggregate payment of $400,000 in 12 equal monthly payments beginning November 2013, and (ii) if the Company sells at least $600,000 of Sorbion sachet products in the 2014 calendar year, $50,000 in January 2015.  This transaction was recorded as the purchase of distribution rights and was recorded as an intangible asset, subject to amortization over the remaining useful life of sixty-three months, and a corresponding liability of $400,000. In consideration of this agreement, an upfront fee of $50,000 for sales and training materials, was expensed in the year ended December 31, 2013 as a selling, general and administrative expense. As of December 31, 2013, the balance of distribution rights payable was $333,333.
	Celgene License, Marketing and Development and Supply Agreement
	In November 2013, the Company entered into a License, Marketing and Development Agreement (the “License Agreement”) with  Anthrogenesis  Corporation,  d/b/a  Celgene  Cellular  Therapeutics  (“CCT”),  an  affiliate  of  Celgene,  pursuant  to  which  CCT  granted  the Company an exclusive, royalty-bearing license in its intellectual property of certain placental based products, including ECMs, an extracellularmatrix derived from the human placenta, and Biovance, CCT’s proprietary wound coverings produced from decellularized, dehydrated humanamniotic  membrane,  to  develop  and  commercialize  ECMs  and  Biovance  in  the  United  States.   Following the commencement of commercial sales of the licensed products, the Company will pay CCT annual license fees, designated amounts when certain milestone events occur and royalties on all sales of licensed products, with such amounts being variable and contingent on various factors. The initial term of the License Agreement ends on November 14, 2023, unless sooner terminated pursuant to the termination rights under the License Agreement, and will extend for additional two-year terms unless either party gives written notice within a specified period prior to the end of a term.  The License Agreement may be terminated (i) by CCT if the Company or any of its affiliates challenges the validity, enforceability or scope of certain enumerated CCT patents anywhere in the world; (ii) by either party if there is a final decree that a licensed product infringed on the intellectual property of a third party; (iii) by either party for breach of the License Agreement, if the breach is not cured within a  specified  period  after  receiving  written  notice  of  the  breach;  or  (iv)  by  either  party  if  the  other  party is  the  subject  of  insolvency proceedings,  either voluntary or involuntary.    In  addition,  the   License  Agreement  is  terminable  on  a  product-by-product  basis,  and  not  with respect to the entire License Agreement (i) by CCT in the second year of the License Agreement, and by either CCT or the Company in the third year of the License Agreement and beyond, if the Company fails to meet certain sales thresholds and (ii) by either party upon written notice if outside legal counsel recommends discontinuance of commercialization of a product because of significant safety, legal, or economic risk as a result of a claim, demand or action or as a result of a change in the interpretation of law by a governmental or regulatory authority. The License Agreement also contains mutual confidentiality and indemnification obligations for the Company and CCT.
	In November 2013, the Company also entered into a Supply Agreement (the “Supply Agreement”) with CCT, pursuant to which CCT shall supply the Company with the Company’s entire requirements of Biovance for distribution and sale in the United States.  The Supply Agreement also provides that the Company and CCT will enter into a supply agreement for ECMs, on substantially the same terms as the Supply Agreement, prior to the anticipated date on which all regulatory approvals or clearances are acquired for the commercial sale of ECMs.  The  Supply  Agreement  will  be  terminated  automatically  upon  the  termination  of  the  License  Agreement  and  may  otherwise  be terminated (i) by CCT upon six months’ prior written notice, (ii) by the Company upon six months’ prior written notice if CCT fails to deliver at least a specified portion of a firm purchase order by the required delivery date specified in the order on at least a specified number of occasions in a specified period; (iii) by either party for breach of the Supply Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary.
	In connection with the License and Supply Agreements, the Company entered into a Stock Purchase Agreement with Celgene Corporation in which the Company sold an aggregate of 1,672,474 shares of the Company’s common stock, and a five year warrant to purchase 836,237 shares of common stock at an exercise price of $5.69 per share, in exchange for aggregate consideration of $6,000,000. See Note 10 – Stockholders’ Equity.
	Litigation, Claims and Assessments
	The Company is subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business.
	On February 27, 2014, ConvaTec Inc. filed suit against the Company and three of its current employees (each a former employee of ConvaTec Inc.), requesting injunctive relief for allegations involving breach of contract, tortious interference with employment agreements, unfair competition and common law conspiracy. ConvaTec Inc. is seeking, among other things, to enjoin the Company from continuing to employ a sales manager who is a former employee of ConvaTec, Inc. in a position related to wound care products and two sales representatives in positions related to wound care products in certain geographic areas.
	The Company intends to fully dispute the allegations of ConvaTec Inc. and the relief sought to the fullest extent permitted by the law and believes them to be wholly without merit.  The Company does not believe that the results of this suit will have a material adverse impact on its financial position, results of operations or cash flows.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders Equity Note [Abstract]	'
Stockholders Equity Note Disclosure [Text Block]	'
		10	Stockholders’ Equity
	Preferred Stock
	The Company has authorized 1,000,000 shares of preferred stock, $0.001 par value per share, which may be divided into series and with preferences, limitations and relative rights determined by the Board of Directors.
	On October 22, 2013, as amended on November 6, 2013, the Company issued 250,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”) and a five-year warrant to purchase 126,984 shares of common stock at an exercise price of $4.38 per share (the “Investor Warrant”) to an accredited investor in exchange for $1,000,000. The stated value of the Preferred Stock was $4.00 per share and it accrued dividends at the rate of 6% per annum. Each share of Preferred Stock was convertible by the investor at any time into common stock at an initial conversion price of $3.94 per share. In connection with the closing of the sale of the Preferred Stock and Investor Warrant, the Company paid $70,000 in cash fees to the Company’s placement agent (the “Placement Agent”) and issued a five-year warrant to purchase 8,889 shares of common stock at an exercise price of $4.38 per share and a five-year warrant to purchase 8,889 shares of common stock at an exercise price of $4.81 per share to the Placement Agent.
	On November 18, 2013, the Company closed on a private placement of equity securities (see below for additional details) which, pursuant to the terms of the Preferred Stock, triggered (i) an adjustment of the Preferred Stock conversion price to $3.59 per share of Common Stock; and (ii) mandatory conversion of the Preferred Stock into 279,505 shares of common stock (the “Conversion Shares”), which represents the $1,000,000 principal amount, plus a 6% dividend of $2,724, divided by the $3.59 adjusted conversion price.
	The Preferred Stock was initially classified as mezzanine (or temporary) equity on the balance sheet, because the Company was obligated to redeem the Preferred Stock on October 21, 2015 if the holders did not elect to convert the Preferred Stock into common stock prior to that date. The Preferred Stock was eventually recorded net of a $573,188 discount, which was comprised of a $113,906 issuance cost discount and a $459,282 discount associated with the issuance of related equity instruments. The $113,906 issuance cost discount represented $70,000 of cash and the $43,906 value of the warrants issued to the Placement Agent. The $459,282 equity instrument discount was comprised of the $240,507 relative fair value of the Investor Warrant, the $129,396 value of the initial beneficial conversion feature and the $89,379 value of the contingent beneficial conversion feature. The aggregate beneficial conversion feature represented the difference between the $978,268 commitment date value of the Conversion Shares (279,505 shares times the $3.50 closing price of the Company’s common stock on October 22, 2013) and the $759,493 accounting conversion price of the Conversion Shares ($1,000,000 proceeds less the $240,507 relative fair value of the Investor Warrant). The Warrants were valued using the Black-Scholes option pricing model using the following assumptions: October 22, 2013 closing common stock price of $3.50 per share, an expected term equal to the five-year contractual term; volatility of 99.44%; a 0% annual rate of quarterly dividends and a 1.3% risk-free interest rate. On the conversion date, the full $459,282 equity instrument discount was recognized as a deemed dividend and the remaining carrying value of the Preferred Stock was reclassified to permanent equity.
	The Investor Warrant will be automatically exercised on the date that the closing price of the common stock equals or exceeds 2.5 times the then-applicable exercise price for a period of sixty consecutive trading days; provided, that, at such time, the Company has an effective registration statement for the resale of the shares of common stock issuable upon exercise of the Investor Warrant (the “Warrant Shares”) or the Warrant Shares may be offered for sale to the public without any volume restrictions. The Investor Warrant is exercisable at any time on a cashless basis.
	Authorized Common Stock
	Effective September 25, 2013, the authorized shares of the Company’s common stock was increased from 11,428,571 shares to 45,714,286 shares, with a $0.001 par value per share.
	Common Stock and Warrant Offerings
	The following table summarizes the common stock and warrant offerings during the years ended December 31, 2013 and 2012:
												Five-Year Warrants
										Common		Investor		Placement Agent
	Issuance			Gross			Issuance			Stock		Warrants		Warrants		Exercise
	Date			Proceeds			Costs			(Shares)		(Shares)		(Shares)		Price
	2/16/12			$	1,050,000		$	62,975		480,000		240,000		25,360		$	3.02
	8/14/12	[1]			265,000			-		121,143		60,571		-		$	2.19
	9/28/12	[2]			25,000			-		11,429		5,714		-		$	2.19
	10/11/12	[2]			5,000			-		2,286		1,143		-		$	2.19
	11/8/12	[3]			815,000	[4]		24,500		372,572		372,572	[5]	8,000	[5]	$	2.19
	2012 Total				2,160,000			87,475		987,430		680,000		33,360
	2/22/13				380,500			-		107,372		107,372		-		$	4.24
	4/11/13				236,000			37,100		66,596		66,596		6,660		$	4.24
	4/22/13				576,000			55,100		162,540		162,540		13,150		$	4.24
	5/31/13				288,000			31,300		81,270		81,270		8,127		$	4.24
	6/28/13				1,976,925			62,632		557,862		557,862		17,674		$	4.24
	11/14/13				6,000,000	[6]		-		1,672,474		836,237		-		$	5.69
	11/18/13				7,000,000			494,000		1,951,220		975,610		136,490		$	5.69
	2013 Total				16,457,425			680,132		4,599,334		2,787,487		182,101
	Total			$	18,617,425		$	767,607		5,586,764		3,467,487		215,461
		[1]	Includes 86,857 shares of common stock and five-year warrants to purchase 43,429 shares of common stock at an exercise price of $2.19 per share issued to certain officers and members of the Board of Directors in exchange for gross proceeds of $190,000.
		[2]	Issued to a member of the Board of Directors.
		[3]	Includes 89,143 shares of common stock and five-year warrants to purchase 89,143 shares of common stock at an exercise price of $2.19 per share issued to certain members of the Board of Directors for gross proceeds of $195,000.
		[4]	Includes $50,000 represented by the conversion of debt.
		[5]	See Note 15 – Fair Value Measurement for details regarding the fair value of the warrant liability recorded in connection with these issued warrants.
		[6]	See Note 9 – Commitment and Contingencies for details regarding the Celgene License, Marketing, and Development Agreement and Supply Agreement.
	The securities purchase agreements the Company entered into in 2012 contain a variety of contractual provisions, which include certain affirmative and negative covenants made by the Company. The Company’s covenants principally consist of a requirement to reserve sufficient authorized shares to issue upon the exercise of the related warrants, and, subject to certain exceptions, in the event the Company subsequently issues or sells common shares at a price lower than the purchase price per share which was offered to the investors, each investor will be entitled to additional shares such that the total purchase price paid by such investor, when divided by the number of shares held by such investor (including additional shares) equals the lower price.
	In connection with the securities purchase agreements entered into on February 16, 2012 and November 8, 2012, pursuant to which Palladium Capital Advisors, LLC served as the placement agent, the Company is required to (i) upon its failure to provide for the timely delivery of shares upon the exercise of the warrants, pay liquidated damages consisting of a cash payment of $10 per trading day (increasing to $20 per trading day on the fifth trading day) for each $1,000 of warrant shares until such certificates are delivered, (ii) upon its failure to maintain timely required filings with the SEC, pay liquidated damages consisting of a cash payment of one percent (1.0%) of the aggregate subscription amount of such purchasers’ securities on the day of the failure to maintain timely filings with the SEC and on every thirtieth (30th) day thereafter, until the required documents are filed with the SEC or such filing is no longer required for the purchaser to transfer the underlying shares pursuant to Rule 144, and (iii) upon its failure to provide for the timely delivery of unlegended shares, upon the satisfaction of certain conditions, pay in cash to the investor (in addition to any other remedies available to or elected by the investor) the amount, if any, by which (A) such investor’s total purchase price (including any brokerage commissions) for the common stock the investor was required to purchase to cover a sale order exceeds (B) the aggregate purchase price of the common shares or warrant shares delivered to the Company for reissuance as unlegended shares.
	The securities purchase agreement for each of the above 2013 financings contain customary representations, warranties and covenants. In addition, the securities purchase agreement for 2013 transactions prior to November 2013 contain a “full ratchet” anti-dilution adjustment provision, pursuant to which, in the event that the Company sells or issues shares of common stock or common stock equivalents at a price (the “Base Price”) lower than $3.54 per share, the Company will be required to issue to each investor, for no additional consideration, a certain number of shares of common stock such that the purchase price paid by such investor under the securities purchase agreement for the number of shares originally held, when divided by the aggregate number of shares originally held and any additional shares issued to such investor, will equal the Base Price. This investor right will terminate for an investor at any time following the nine month anniversary of the final closing under such investor’s securities purchase agreement, if (i) the closing sales price of the common stock for thirty (30) consecutive trading days is at least 200% of the per share purchase price, (ii) the product of (A) the volume weighted average price of the common stock on its principal market and (B) its corresponding daily trading volume, each as reported by Bloomberg L.P., equals or exceeds $50,000 for such thirty (30) consecutive trading days and (iii) the investor shares that were acquired by investors who are not our affiliates were eligible for unrestricted sale pursuant to Rule 144 under the Securities Act of 1933, as amended on the Company’s principal market from the six month anniversary of the final closing under the securities purchase agreement through at least the nine month anniversary of such final closing. Each warrant is exercisable immediately for cash. In addition, in the event that there is no effective registration statement registering, or no current prospectus available for, the resale of the shares of common stock issuable upon exercise of a warrant at any time following the one year anniversary of the issuance date of such warrant, such warrant may also be exercised by way of a cashless exercise. The warrants also contain customary provisions that protect their holders against dilution by adjustment of the purchase price in certain events such as stock dividends, stock splits and other similar events.
	Stock-Based Compensation
	The following table summarizes stock-based compensation expense, which is reflected as selling, general and administrative expenses in the consolidated statements of operations:
			For The Years Ended
			December 31,
			2013			2012
	Options		$	3,948,025		$	1,421,338
	Warrants			172,913			3,777
	Restricted Stock Units			83,836			-
	Restricted Stock			1,309,087			550,000
	Total Stock-Based Compensation		$	5,513,861		$	1,975,115
	Restricted Stock
	The following table summarizes the restricted stock issued as compensation during the years ended December 31, 2013 and 2012:
	Issuance		Grantee		Shares		Vesting			Grant Date
	Date		Type		Issued		Term			Value
	1/11/12		Vendor		45,714		Immediate		$	100,000	[1]
	6/30/12		Officer		22,857		Immediate			100,000
	6/30/12		Officer		32,653		Immediate			100,000
	8/15/12		Consultant		2,286		Immediate			10,000
	9/20/12		Consultant		2,286		Immediate			10,000
	11/14/12		Consultant		4,571		Immediate			20,000
	11/14/12		Consultant		45,714		Immediate			200,000
	11/30/12		Consultant		2,286		Immediate			10,000
			Restricted Stock - Total		158,367					550,000
	11/8/12		Officer		70,753		[2]			154,773
		Restricted Stock Units - Total		70,753					154,773
		2012 - Total		229,120					704,773
5/24/13		Consultant		2,286		Immediate			7,000
6/28/13		Fmr. Officer		186,165		Immediate			570,130
7/1/13		Consultant		16,429		Immediate			50,312
10/15/13		Consultant		3,265		Immediate			10,000
11/11/13		Fmr. Officer		186,165		Immediate			651,578
11/14/13		Consultant		2,875		Immediate			10,063
12/12/13		Employee		21,614		One year			150,001	[3]
12/24/13		Consultant		1,409		Immediate			10,004
		Restricted Stock - Total		420,208					1,459,088
		2013 - Total		420,208				$	1,459,088
	[1]	See Note 13 –Related Party Transactions for additional details.
	[2]	Vests over three years and is subject to the Company’s achievement of certain market capitalization targets.  During the fourth quarter of 2013, 35,377 shares vested as a performance condition was met.
	[3]	Shares forfeited during 2013. The Company did not record any stock-based compensation expense during 2013 related to the issuance.
As of December 31, 2013, there was $23,646 of unrecognized stock-based compensation expense related to RSUs which will be amortized over a weighted average period of 1.8 years, provided the performance condition remains probable of being achieved. Separately, as of December 31, 2013, there was $38,693 of unrecognized stock-based compensation expense related to RSUs with performance conditions that are currently improbable of being achieved.
Warrants
See Note 10 – Stockholders’ Equity - Preferred Stock, Common Stock and Warrant Offerings for details of warrants issued to investors and placement agents in connection with equity offerings.
On April 10, 2012, the Company entered into an agreement for investment banking services. The agreement had a term of twelve months. As compensation for services, the Company agreed to pay a cash fee of $6,500 per month and a five-year warrant to purchase 1,143 shares of common stock at an exercise price $3.50 per share was to be issued monthly. During 2012, the Company issued warrants to purchase an aggregate of 2,286 shares of common stock with an aggregate grant date value of $3,777. The grant date value was recognized immediately. A warrant to purchase an additional 1,143 shares of common stock was waived by the receiving party due to non-performance. The agreement was terminated in July of 2012.
On July 11, 2013, the Company issued to a consultant a five-year warrant to purchase 6,857 shares of common stock at an exercise price of $4.38 per share, which will vest and become exercisable in 12 equal monthly installments over the first year from the date of issuance. The aggregate grant date value was $14,640.
Between October 28 and November 12, 2013, the Company issued to various consultants five-year warrants to purchase an aggregate of 68,571 shares of common stock at exercise prices ranging from $4.38 to $5.69 per share.  The warrants vest in twelve equal monthly installments from the date of issuance.  The aggregate grant date value was $168,255.
In applying the Black-Scholes option pricing model to compensatory warrants issued, the Company used the following weighted average assumptions:
		For The Year Ended
		December 31,
		2013		2012
Risk free interest rate		1.27	%	0.74	%
Expected term (years)		5		5
Expected volatility		99.59	%	98.49	%
Expected dividends		0	%	0	%
The risk-free interest rate is based on rates of treasury securities with the same expected term as the warrants. The expected term used for warrants is the contractual life. The Company is utilizing an expected volatility figure based on a review of the Company’s historical volatility, over a period of time, equivalent to the expected life of the instrument being valued. The expected dividend yield is based upon the fact that the Company has not historically paid dividends, and does not expect to pay dividends in the near future.
The weighted average estimated fair value per share of the compensatory warrants issued during the year ended December 31, 2013 and 2012 was $2.42 and $1.65, respectively.
During the year ended December 31, 2013, the Company issued an aggregate of 261,030 shares of common stock to several holders of warrants who elected to exercise warrants to purchase an aggregate of 371,429 shares of common stock on a "cashless" basis under the terms of the warrants. The warrants had exercise prices of $3.02 per share (125,714 gross shares) and $2.19 per share (245,715 gross shares). The aggregate intrinsic value of the warrants exercised was $2,167,657 for the year ended December 31, 2013.
As of December 31, 2013, there was $255,537 of unrecognized stock-based compensation expense related to compensatory warrants that are subject to non-employee mark-to-market adjustments and will be amortized over a weighted average period of 0.9 years.
A summary of the warrant activity, including common stock purchase warrants, during the years ended December 31, 2013 and 2012 is presented below:
							Weighted
				Weighted			Average
				Average			Remaining
		Number of		Exercise			Life		Intrinsic
		Warrants		Price			In Years		Value
Outstanding, December 31, 2011		310,107		$	10.94
Issued		715,647			2.63
Anti-Dilutive Adjustment		539			51.19
Exercised		-			-
Forfeited		-22,085			51.19
Outstanding, December 31, 2012		1,004,208		$	3.94
Issued		3,189,778			5.15
Exercised		-371,429			1.01
Forfeited		-			-
Outstanding, December 31, 2013		3,822,557		$	5.12		4.4		$	8,369,579
Exercisable, December 31, 2013		3,756,558		$	5.12		4.4		$	8,207,235
The following table presents information related to warrants at December 31, 2013:
Warrants Outstanding					Warrants Exercisable
					Weighted
			Outstanding		Average		Exercisable
Exercise			Number of		Remaining Life		Number of
Price			Warrants		In Years		Warrants
$	2.19		202,286		3.8		202,286
	3.02		139,648		3.1		139,648
	3.5		2,286		3.3		2,286
	4.24		1,021,251		4.4		1,021,251
	4.38		188,444		4.8		143,112
	4.81		8,889		4.8		8,889
	5.69		1,971,194		4.9		1,950,527
	7		140,708		1.4		140,708
	8.75		147,851		1.4		147,851
			3,822,557		4.4		3,756,558
As of December 31, 2013, five-year warrants to purchase an aggregate of 152,000 shares of common stock at an exercise price of $2.19 per share were deemed to be a derivative liability. See Note 15 – Fair Value Measurement

Stock_Options

Stock Options	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
		11	Stock Options
	Options - 2011 Plan
	The Company maintains an active stock option plan (the “2011 Plan”) that provides for option grants to employees, directors and others.  A total of 1,828,571 shares of common stock have been authorized for issuance under the 2011 Plan, of which, as of December 31, 2013, 681,053 shares were reserved for outstanding options and 1,147,518 shares were available for future option issuances. As of December 31, 2013, an inactive stock option plan had 352,191 shares reserved for outstanding options (no shares were available for future option issuances), while there were 3,952,342 shares reserved for non-plan outstanding options.
	Options - 2012 Grants
	During 2012, options to purchase an aggregate of 1,979,576 shares of common stock at exercise prices ranging from $4.38 to $8.75 with an aggregate grant date value of $3,056,383 were granted to directors, employees and consultants.  Most of the 2012 grants had five or ten year terms and vested between immediately or within three years.  In general, the grant date value is being amortized over the vesting term.
	Details of the grants with the more significant grant date values are as follows:
		-1	On May 17, 2012, a ten-year option to purchase 530,286 shares of common stock with an aggregate grant date value of $914,080 was granted to a director.  The options were scheduled to vest and become exercisable as follows: (i) options to purchase 79,543 shares of common stock at $4.38 per share vested immediately on the date of grant; and (ii) the remainder were to vest and become exercisable at $4.38 or $6.56 per share based on various performance measures that were never met or were cancelled based on mutual agreement.
		-2	On November 27, 2012, a ten-year option to purchase 457,143 shares of common stock with an aggregate grant date value of $695,000 was granted to a director.  The options were scheduled to vest and become exercisable as follows: (i) options to purchase 57,143 shares of common stock at $8.75 per share vested immediately on the date of grant; (ii) options to purchase 57,143 shares of common stock at $8.75 per share vest on each of the one-, two-, and three-year anniversaries of the date of grant; (iii) options to purchase 57,143 shares of common stock at $8.75 per share vested on November 14, 2013 upon meeting a performance condition and (iv) the remainder were to vest based on various performance measures that were never met or were cancelled based on mutual agreement.
		-3	On November 5, 2012, a ten-year option to purchase 212,261 shares of common stock with an aggregate grant date value of $318,833 was granted to an officer of the Company.  The options are scheduled to vest and become exercisable at $4.38 per share on each of the one- (70,754 shares), two- (70,754 shares), and three-year (70,753 shares) anniversaries of the date of grant.
		-4	On November 29, 2012, a ten-year option to purchase 177,600 shares of common stock with an aggregate grant date value of $292,670 was granted to a director of the Company.  The options are scheduled to vest and become exercisable as follows: (i) options to purchase 59,200 shares at $4.38 per share vested immediately; and (ii) options to purchase 59,200 shares of common stock vest on each of the one- (at $6.56 per share) and two- (at $8.75 per share) year anniversaries of the date of grant.
	Options - 2013 Grants
	During 2013, options to purchase an aggregate of 3,319,421 shares of common stock at exercise prices ranging from $3.28 to $10.94 (most between $4.38 and $8.75) with an aggregate grant date value of $9,375,010 were granted to directors, employees and consultants.  Most of the 2013 grants had five or ten year terms and vested between immediately or within three years.  In general, the grant date value is being amortized over the vesting term.
	Details of the grants with the more significant grant date values are as follows:
		-1	On December 20, 2013, a ten-year option to purchase 730,535 shares of common stock with an aggregate grant date value of $3,826,039 was granted to an officer of the Company.  The options are scheduled to vest and become exercisable at $6.82 per share as follows: (i) 81,171 shares on January 1, 2014 and (ii) 81,170 or 81,171 shares on each of the next eight succeeding quarterly anniversaries of the first vesting date.
		-2	On July 22, 2013, a 9.5-year option to purchase 622,170 shares of common stock with an aggregate grant date value of $1,556,984 was granted to a director.  The options were scheduled to vest and become exercisable as follows: (i) options to purchase 207,290 shares of common stock at $6.56 per share are currently deemed probable of vesting upon the meeting of certain performance criteria; (ii) options to purchase 207,290 shares of common stock at $8.75 per share are currently deemed probable of vesting upon the meeting of certain performance criteria; (iii) options to purchase 207,290 shares of common stock at $10.94 per share are also currently deemed probable of vesting upon the meeting of certain performance criteria.  In conjunction with this grant, certain outstanding options with as yet unmet 2013 performance conditions held by this director were cancelled, as follows: (a) options to purchase 106,057 shares of common stock at $6.56 per share; (b) options to purchase 114,286 shares of common stock at $8.75 per share; and (c) options to purchase 57,142 shares of common stock at $8.75 per share.
		-3	On February 4, 2013, a ten-year immediately vested option to purchase 279,227 shares of common stock at an exercise price of $3.18 per share with an aggregate grant date value of $684,107 was granted to an officer of the Company.
		-4	On May 10, 2013, a ten-year option to purchase 274,275 shares of common stock with an aggregate grant date value of $476,794 was granted to an officer of the Company.  The options were scheduled to vest and become exercisable (the exercise price for one-fifth of each tranche is $4.38, $5.47, $6.56, $8.75 and $10.94 per share) as follows: (i) options to purchase 54,855 shares of common stock vested immediately on the date of grant; (ii) options to purchase 54,855 shares of common stock vest on each of the one-, two-, three-, and four-year anniversaries of the date of grant.
		-5	On September 3, 2013, a ten-year option to purchase 185,142 shares of common stock with an aggregate grant date value of $384,210 was granted to an officer of the Company.  The options are scheduled to vest and become exercisable as follows: (i) options to purchase 61,714 shares at $4.38 per share vested immediately; and (ii) options to purchase 61,714 shares of common stock vest on each of the one- (at $6.56 per share) and two- (at $8.75 per share) year anniversaries of the date of grant.
		-6	On November 14, 2013, a five-year option to purchase 160,000 shares of common stock with an aggregate grant date value of $371,992 was granted to a consultant of the Company.  The options are scheduled to vest and become exercisable as follows: (i) options to purchase 80,000 shares at $5.69 per share vested immediately; and (ii) options to purchase 80,000 shares at $6.56 per share vest on the six month anniversary of the date of grant.
		-7	On November 14, 2013, a ten-year option to purchase 117,125 shares of common stock with an aggregate grant date value of $310,482 was granted to an officer of the Company.  The options are scheduled to vest and become exercisable at $3.50 per share as follows: (i) options to purchase 32,549 shares on March 28, 2014 (ii) options to purchase 41,116 shares on June 28, 2014; and (iii) options to purchase 43,460 shares on September 30, 2014.
		-8	On May 10, 2013, a ten-year option to purchase 171,432 shares of common stock with an aggregate grant date value of $292,406 was granted to an employee of the Company.  The options were scheduled to vest and become exercisable (the exercise price for one-fourth of each tranche is $4.38, $5.47, $6.56 and $8.75 per share) as follows: (i) options to purchase 57,144 shares of common stock vested immediately on the date of grant and (ii) options to purchase 57,144 shares of common stock vest on each of the one- and two-year anniversaries of the date of grant.
	Options - Summary Data
	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:
			For The Years Ended
			December 31,
			2013		2012
	Risk free interest rate		1.4	%	0.75	%
	Expected term (years)		5.55		5.49
	Expected volatility		99.78	%	97.87	%
	Expected dividends		0	%	0	%
	The risk-free interest rate is based on rates of treasury securities with the same expected term as the options. The Company uses the "simplified method" to calculate the expected term of employee and director stock-based options. The expected term used for consultants is the contractual life. The Company is utilizing an expected volatility figure based on a review of the Company’s historical volatility, over a period of time, equivalent to the expected life of the instrument being valued. The expected dividend yield is based upon the fact that the Company has not historically paid dividends, and does not expect to pay dividends in the near future.
	The weighted average estimated fair value per share of the options granted during the year ended December 31, 2013 and 2012 was $2.80 and $1.54, respectively.
	During the year ended December 31, 2013, the Company recognized a credit of $411,614 relating to options containing performance conditions, of which, $386,119 related to previously recognized expense for options where the performance was not rendered by the required date and have been forfeited, and $25,495 related to the expense previously recognized for options which were originally deemed probable of being achieved that are now deemed improbable of being achieved. As of December 31, 2013, there was $6,609,208 of unrecognized stock-based compensation expense related to stock options which will be amortized over a weighted average period of 1.6 years, of which $536,764 is subject to non-employee mark-to-market adjustments. Separately, as of December 31, 2013, there was $137,332 of unrecognized stock-based compensation expense related to stock options with performance conditions that are currently improbable of being achieved.
	A summary of the stock option activity during the years ended December 31, 2013 and 2012 is presented below:
							Weighted
					Weighted		Average
					Average		Remaining
			Number of		Exercise		Life	Intrinsic
			Options		Price		In Years	Value
	Outstanding, December 31, 2011		431,314		$	7
	Granted		1,979,576			6.13
	Exercised		-			-
	Forfeited		-77,068			4.81
	Outstanding, December 31, 2012		2,333,822		$	6.56
	Granted		3,319,421			6.37
	Exercised		-			-
	Forfeited		-667,657			6.96
	Outstanding, December 31, 2013		4,985,586		$	6.47	8.2	$	6,574,508
	Exercisable, December 31, 2013		2,381,469		$	5.87	6.9	$	4,241,527
	The following table presents information related to stock options at December 31, 2013:
	Options Outstanding					Options Exercisable
						Weighted
				Outstanding		Average	Exercisable
		Exercise		Number of		Remaining Life	Number of
	Price			Options		In Years	Options
	$	3.28		279,227		9.1	279,227
		3.5		117,125		-	-
		3.94		7,619		9.9	7,619
		4.38		1,233,854		6.4	853,325
		5.47		120,569		9.4	30,971
		5.69		114,286		4.9	114,286
		5.91		17,142		7	17,142
		6.34		280,342		5.9	280,342
	6.56		657,634		5	205,599
	6.82		780,535		10	12,500
	8.75		999,349		8.7	453,828
	9.19		114,285		4.9	114,285
	10.94		262,245		9.4	10,971
	11.38		1,145		4.7	1,145
	26.69		229		4.4	229
			4,985,586		6.9	2,381,469

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
		12	Income Taxes
	The income tax provision (benefit) consists of the following:
			For The Years Ended
			December 31,
			2013		2012
	Federal:
	Current		$	-	$	-
	Deferred			-6,528,000		-1,648,000
	State and local:
	Current			-		-
	Deferred			-1,140,000		-139,000
				-7,668,000		-1,787,000
	Change in valuation allowance			7,677,000		1,798,000
	Income tax provision (benefit)		$	9,000	$	11,000
	The expected tax expense (benefit) based on the statutory rate reconciled with the actual expense (benefit) is as follows:
			For The Years Ended
			December 31,
			2013		2012
	US federal statutory rate		-34	%	-34	%
	State tax rate, net of federal benefit		-5.9	%	-5.9	%
	Permanent differences
	- Exercised warrant liability		3.3	%	0	%
	- Other		1.7	%	3.4	%
	Change in valuation allowance		34.9	%	36.7	%
	Income tax provision (benefit)		0	%	0.2	%
	Deferred tax assets consisted of the effects of temporary differences attributable to the following:
			As of December 31,
			2013		2012
	Deferred tax assets:
	Net operating loss carryforwards		$	10,703,000	$	7,940,000
	Stock-based compensation			2,825,000		1,469,000
	Intangible assets			4,059,000		870,000
	Accruals			326,000		-
	Other			230,000		196,000
	Total deferred tax assets			18,143,000		10,475,000
	Valuation allowance			-17,607,000		-9,930,000
	Deferred tax assets, net of valuation allowance			536,000		545,000
	Deferred tax liabilities:
	Property and equipment			-536,000		-545,000
	Goodwill			-53,000		-44,000
	Total deferred tax liabilities			-589,000		-589,000
	Net deferred tax liabilities		$	-53,000	$	-44,000
	For the years ended December 31, 2013 and 2012, the Company had approximately $27,408,000 and $20,468,000 of federal and state net operating loss carryovers (“NOLs”), respectively, which begin to expire in 2018. The net operating loss carryovers may be subject to annual limitations under Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under the regulations. The Company conducted a preliminary Section 382 analysis and has determined that no ownership changes have occurred wherein the annual limitations will inhibit the Company from ultimately realizing the benefit of NOL's if the Company generates sufficient taxable income.
	In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the future generation of taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and taxing strategies in making this assessment. The deferred tax liability related to goodwill cannot be used in this determination since goodwill is considered to be an asset with an indefinite life for financial reporting purposes. Therefore, the deferred tax liability related to goodwill cannot be considered when determining the ultimate realization of deferred tax assets. Based upon this assessment, management has established a full valuation allowance for the amount of the deferred tax assets which cannot be supported through the production of future taxable income generated through the reversal of the deferred tax liability related to the depreciation of the property and equipment, since it is more likely than not that these deferred tax assets will not be realized.

Related_Party

Related Party	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
		13	Related Party
	On January 11, 2012, the Company issued 45,714 shares of common stock to a related party in satisfaction of its obligation for office space and services.
	On February 15, 2013, a subscription receivable of $20,000 was received from a director in connection with a private placement.
	On February 22, 2013, the Company issued to four directors and an affiliate of a director, in the aggregate, (i) 76,190 shares of common stock and (ii) five year warrants to purchase, in the aggregate, up to 76,190 shares of common stock at an exercise price of $4.24 per share, in exchange for aggregate consideration of $270,000.
	On June 28, 2013, the Company issued to five directors, in the aggregate, (i) 231,393 shares of common stock and (ii) five year warrants to purchase, in the aggregate, up to  231,393 shares of common stock at an exercise price of $4.24 per share, in exchange for aggregate consideration of $820,000.

Concentration_of_Risk

Concentration of Risk	12 Months Ended
	Dec. 31, 2013
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
		14	Concentration of Risk
	Revenues and accounts receivable from our largest customers for the years ended December 31 were as follows:
			2013				2012
	Customer		% of Total Revenue		Accounts Receivable		% of Total Revenue		Accounts Receivable
	A		51	%	51	%	60	%	38	%
	B		16	%	0	%	16	%	39	%
	Principal components used in manufacturing are purchased from the following sources: Berry Plastics, Dow Chemical and BASF.  The total material purchases from these sources were $203,239 and $124,552 for the years ended December 31, 2013 and 2012, respectively.

Fair_Value_Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
		15	Fair Value Measurement
	On December 31, 2012, the Company recomputed the fair value of its warrant liability as $605,737 using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 97.26%, risk-free rate of 0.65%, expected term of 5.00 years, and expected dividends of 0.00%. The change in fair value of these warrant liabilities for the year ended December 31, 2012 was de minimis.
	On December 2, 2013, warrants to purchase an aggregate of 228,572 shares of common stock were exercised. These warrant liabilities had an aggregate exercise date fair value of $1,505,770 which was credited to equity. The Company recorded a loss on the change in fair value of these warrant liabilities of $1,141,964 during the year ended December 31, 2013. The Company recomputed the fair value of these warrant liabilities using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 99.44%, risk-free rate of 1.01%, expected term of 3.94 years, and expected dividends of 0.00%.
	On December 31, 2013, the Company recomputed the fair value of its warrant liability as $933,465 using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 102.63%, risk-free rate of 1.27%, expected term of 3.86 years, and expected dividends of 0.00%. The Company recorded a loss on the change in fair value of these warrant liabilities of $691,534 during the year ended December 31, 2013.
	The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis:
			December 31,
			2013			2012
	Beginning balance as of January 1,		$	605,737		$	-
	Aggregate value of warrants issued			-			605,737
	Change in fair value of warrant liability			1,833,498			-
	Value of warrants exercised			-1,505,770			-
	Ending balance as of December 31,		$	933,465		$	605,737
	Assets and liabilities measured at fair value on a recurring or nonrecurring basis are as follows:
			Level		Level		Level
			1		2		3
	31-Dec-12
	Recurring:
	Warrant liabilities		N/A		N/A		$	605,737
	31-Dec-13
	Recurring:
	Warrant liabilities		N/A		N/A		$	933,465
	Warrants that contain exercise reset provisions are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer.

Defined_Contribution_Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Pension and Other Postretirement Benefits Disclosure [Text Block]	'
		16	Defined Contribution Plan
	The Company maintains the AquaMed Technologies, Inc.  401(k) Profit Sharing Plan and Trust (“Plan”) in accordance with the provisions of Section 401(k) of the Internal Revenue Code (“Code”).  The Plan covers substantially all full-time employees of the Company.   Participants may contribute up to 100% of their total compensation to the Plan, not to exceed the limit as defined in the Code.  The Company does not currently provide any Company match, therefore no expenses were recorded in 2013 and 2012.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
		17	Subsequent Events
	On January 6, 2014 the Company entered into an option cancellation and release agreement with two directors, pursuant to which each of the parties agreed to cancel options previously granted to purchase 278,096 shares of common stock of the Company at exercise prices ranging from $6.34 to $9.19.  In exchange for the cancellation of the options, the Company granted each director 194,667 shares of common stock of the Company pursuant to 2011 Plan.
	On January 6, 2014, the Company granted a restricted stock award of 369,395 shares of common stock to the Company’s president and chief executive officer, pursuant to the Company’s 2011 Long-Term Incentive Plan. The restricted stock vests, subject to certain terms and conditions included in the restricted stock agreement, in eight quarterly installments, with one-eighth vesting on January 6, 2014 and the first day of each calendar quarter, thereafter.
	On March 14, 2014 the chief executive officer of a wholly-owned subsidiary of the Company resigned.  In connection with his resignation, the executive entered into a General Release and Severance Agreement with the Company, pursuant to which, the Company will provide the executive with the following: (a) a lump sum payment in the amount of $210,000; (b) severance payments, in an amount equal to his base salary for a period of six months from the date of resignation; (c) continued health insurance coverage for a period of six months; and (d) the full and immediate vesting of all outstanding stock options and restricted stock unit awards granted to the executive with such stock options remaining exercisable for a period of two years following the date of resignation.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates in the Financial Statements
	The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes.   These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, account receivable reserves, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles and goodwill. Actual results could differ from the estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. The Company’s balance of cash and cash equivalents at December 31, 2013 and 2012 consisted principally of bank deposits.  From time to time, the Company’s cash account balances may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation guarantee limit.   The Company reduces its exposure to credit risk by maintaining its cash deposits with major financial institutions and monitoring their credit ratings.
Receivables, Policy [Policy Text Block]	'
	Accounts Receivable
	Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms.  The Company’s accounts receivable balance is a result of product sales and contract manufacturing.  These receivables have historically been paid timely.  Due to the nature of the accounts receivable balance, the Company believes there is no significant risk of collection.  If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, allowances for doubtful accounts would be required.
Inventory, Policy [Policy Text Block]	'
	Inventory
	Inventory is valued at the lower of cost or market on a first-in, first-out basis. Reserves for inventory obsolescence are based on expiration date and are utilized to account for slow-moving inventory.   At December 31, 2013 and 2012, the Company had reserves for obsolete inventory of $76,580 and $17,650, respectively.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Improvements and Equipment
	Improvements and equipment are recorded at cost. Depreciation of equipment is computed utilizing the straight-line method over the estimated useful lives of the assets. Amortization of leasehold improvements is computed utilizing the straight-line method over the shorter of the remaining lease term or estimated useful life. Repairs and maintenance costs are expensed as incurred. Additions and betterments are capitalized.
In Process Research and Development, Policy [Policy Text Block]	'
	Acquired In-Process Research and Development
	In-process research and development (“IPR&D”) represents the fair value assigned to incomplete research projects that the Company acquires through business combinations which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&D are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. The Company tests IPR&D for impairment at least annually or more frequently if impairment indicators exist.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	'
	Goodwill and Other Intangible Assets
	The Company accounts for goodwill and intangible assets in accordance with the accounting guidance which requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value.  Goodwill of $425,969 was assigned during the acquisition of Hydrogel Design Systems by AquaMed Technologies, Inc. in 2009.   The Accounting Standards Codification (“Codification”) requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment). Application of the goodwill impairment test requires judgment, including the identification of reporting units, assigning assets and liabilities to reporting units, assigning goodwill to reporting units, and determining the fair value. Significant judgment is required to estimate the fair value of reporting units which includes estimating future cash flows, determining appropriate discount rates and other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value and/or goodwill impairment.
	When testing goodwill for impairment, the Company may assess qualitative factors for some or all of its reporting units to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount, including goodwill. Alternatively, the Company may bypass this qualitative assessment for some or all of our reporting units and perform a detailed quantitative test of impairment (step 1). If the Company performs the detailed quantitative impairment test and the carrying amount of the reporting unit exceeds its fair value, the Company would perform an analysis (step 2) to measure such impairment. In 2013, the Company first performed a qualitative assessment to identify and evaluate events and circumstances to conclude whether it is more likely than not that the fair value of the Company’s reporting unit is less than its carrying amount. Based on the Company’s qualitative assessments, the Company concluded that a positive assertion can be made from the qualitative assessment that it is not more likely than not that the fair value of the reporting unit is less than its carrying amount.  In accordance with the Codification, the Company reviews the carrying value of its intangibles and other long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the asset or asset group to the undiscounted cash flows that the asset or asset group is expected to generate. If the undiscounted cash flows of such assets are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group, if any, exceeds its fair market value. No impairment was deemed to exist as of December 31, 2013.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	'
	Impairment of Long-Lived Assets Subject to Amortization
	The Company amortizes intangible assets with finite lives over their estimated useful lives and reviews them for impairment annually or whenever an impairment exists.  The Company continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. As of December 31, 2013, Company management believed that no revision to the remaining useful lives or write-down of the Company’s long-lived assets was required, and similarly, no such revisions were required for the year ended December 31, 2012.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments.
	Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows:
	Level 1: Observable prices in active markets for identical assets and liabilities.
	Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities.
	Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred; title and risk of loss have passed to the customer, there is a fixed or determinable sales price, and collectability of that sales price is reasonably assured.  Deposits received on product orders are recorded as deferred revenue until revenues are earned when the products are shipped to customers.  For irradiation services, the Company records revenue based upon an hourly service charge as services are provided.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development
	Research and development expenses represent costs incurred to develop technology. Research and development expenses are charged to operations as they are incurred, including internal costs, costs paid to sponsoring organizations, and contract services for any third party laboratory work. Research and development expenses are tracked by project.  As of December 31, 2013 and 2012 research and development costs totaled $63,204 and $233,819, respectively.
Selling, General and Administrative Expenses, Policy [Policy Text Block]	'
	Cost of Goods Sold and Selling, General and Administrative Expenses
	Costs associated with the production and procurement of product are included in cost of goods sold, including shipping and handling costs such as inbound freight costs, purchasing and receiving costs, inspection costs and other product procurement related charges. All other expenses, excluding interest and income taxes, are included in selling, general and administrative expenses, as the predominant expenses associated therewith are general and administrative in nature.
Advertising Cost, Policy, Expensed Advertising Cost [Policy Text Block]	'
	Advertising Expenses
	Advertising and marketing costs are expensed as incurred. Advertising expenses for the years ended December 31, 2013 and 2012 were $298,859 and $139,024, respectively.
Shipping and Handling Cost, Policy [Policy Text Block]	'
	Shipping and Handling
	Shipping and handling costs are paid for by the Company. Shipping and handling costs amounted to approximately $23,523 and $14,635 as of December 31, 2013 and 2012, respectively, and are included in selling, general and administrative expenses.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	The Company accounts for income taxes pursuant to the asset and liability method which requires deferred tax assets and liabilities to be recognized for the expected future tax consequences attributable to temporary differences between the financial statement carrying amounts and their respective tax bases of assets and liabilities.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period enacted. A valuation allowance is provided when it is more likely than not that a portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible.
	The Company adopted the provisions of Accounting Standards Codification Topic 740 (“ASC 740”) related to the accounting for uncertainty in income taxes recognized in an enterprise's consolidated financial statements. ASC 740 prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns.
	The benefit of tax positions taken or expected to be taken in the Company's income tax returns are recognized in the financial statements if such positions are more likely than not of being sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits”. A liability is recognized (or amount of net operating loss carryover or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. Interest costs and related penalties related to unrecognized tax benefits are required to be calculated, if applicable. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as selling, general and administrative expenses. No interest or penalties were recorded during the years ended December 31, 2013 and 2012. As of December 31, 2013 and December 31, 2012, no liability for unrecognized tax benefits was required to be reported. The Company files tax returns in U.S. federal, state and local jurisdictions, including Pennsylvania, and has tax returns subject to examination by tax authorities beginning in the year ended December 31, 2010. The Company does not expect any significant changes in its unrecognized tax benefits in the next year.
Common Stock Purchase Warrant [Policy Text Block]	'
	Common Stock Purchase Warrants
	The Company assesses classification of common stock purchase warrants at each reporting date to determine whether a change in classification between assets and liabilities or equity is required.  The Company’s free standing derivatives consist of warrants to purchase common stock that were issued pursuant to a Securities Purchase Agreement on November 8, 2012.  The Company evaluated the common stock purchase warrants to assess their proper classification in the consolidated balance sheet and determined that the common stock purchase warrants contain exercise reset provisions.  Accordingly, these instruments have been classified as warrant liabilities in the accompanying consolidated balance sheets as of December 31, 2013 and 2012.  The Company re-measures warrant liabilities at each reporting and exercise date, with changes in fair value recognized in earnings for each reporting period.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on interim financial reporting dates and vesting dates until the service period is complete. The fair value amount is then recognized over the period services are required to be provided in exchange for the award, usually the vesting period. The Company recognizes stock-based compensation expense on a graded-vesting basis over the requisite service period for each separately vesting tranche of each award. Stock-based compensation expense is reflected within operating expenses in the consolidated statements of operations. The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment.
Earnings Per Share, Policy [Policy Text Block]	'
	Net Loss Per Common Share
	Basic net loss per common share is computed based on the weighted average number of shares of common stock outstanding during the periods presented. Common stock equivalents, consisting of warrants, stock options and non-vested restricted stock units (“RSUs”), were not included in the calculation of the diluted loss per share because their inclusion would have been anti-dilutive.
	The total common shares issuable upon the exercise of stock options, warrants and non-vested restricted stock units are as follows:
		December 31,
		2013	2012
	Stock Options	4,985,586	2,333,822
	Warrants	3,822,557	1,004,208
	Non-Vested Restricted Stock Units	35,376	70,753
	Total	8,843,519	3,408,783

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	The total common shares issuable upon the exercise of stock options, warrants and non-vested restricted stock units are as follows:
		December 31,
		2013	2012
	Stock Options	4,985,586	2,333,822
	Warrants	3,822,557	1,004,208
	Non-Vested Restricted Stock Units	35,376	70,753
	Total	8,843,519	3,408,783

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventory consists of the following:
		December 31,
		2013		2012
	Raw materials	$	174,176	$	209,820
	Work in process		57,030		25,119
	Finished goods		346,843		102,037
	Less: Inventory reserve		-76,580		-17,650
	Total	$	501,469	$	319,326

Improvements_and_Equipment_net1

Improvements and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Improvements and equipment consist of the following:
			December 31,
		Useful Life	2013		2012
		(Years)
	Machinery and equipment	10	$	2,869,453	$	2,869,453
	Office furniture and equipment	10		44,844		40,124
	Leasehold improvements	(A)		228,021		108,139
				3,142,318		3,017,716
	Less: Accumulated depreciation and amortization			-1,397,070		-1,102,537
	Improvements and equipment, net		$	1,745,248	$	1,915,179
	(A) Leasehold improvements are amortized over the shorter of the remaining lease term or estimated useful life.

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Accrued Liabilities, Current [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued expenses consist of the following:
		December 31,
		2013		2012
	Salaries, benefits and incentive compensation	$	1,036,771	$	230,281
	Professional fees		83,317		11,736
	Inventory		127,786		-
	Other		20,025		7,711
	Total accrued expenses	$	1,267,899	$	249,728

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Finite-Lived Intangible Assets, Net [Abstract]	'
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]	'
	The gross carrying amount and accumulated amortization of intangible assets as of December 31, 2013 and 2012 are as follows:
				December 31,
				2013
										Net
		Useful Life		Gross		Accumulated				Carrying
		(Years)		Amount		Amortization		Impairment		Amount
	In process research and development			$	8,100,000	$	-	$	-8,100,000	$	-
	Technology	10			3,000,000		-1,475,000		-		1,525,000
	Customer relationships	12			600,000		-245,834		-		354,166
	Distribution rights	5.27			400,000		-20,689		-		379,311
				$	12,100,000	$	-1,741,523	$	-8,100,000	$	2,258,477
				December 31,
				2012
										Net
		Useful Life		Gross		Accumulated				Carrying
		(Years)		Amount		Amortization		Impairment		Amount
	In process research and development			$	8,100,000	$	-	$	-	$	8,100,000
	Technology	10			3,000,000		-1,175,000		-		1,825,000
	Customer relationships	12			600,000		-195,833		-		404,167
				$	11,700,000	$	-1,370,833	$	-	$	10,329,167
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Amortization expense in each of the five years and thereafter subsequent to December 31, 2013 related to the Company’s intangible assets is expected to be as follows:
		Expected
		Amortization
		Expense
	2014	$	426,190
	2015		426,190
	2016		426,190
	2017		426,190
	2018		424,548
	Thereafter		129,169
	Total	$	2,258,477

Operating_Leases_Tables

Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2013
Leases, Operating [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	Future minimum lease payments, excluding expense reimbursements, under noncancelable operating leases in each of the five years and thereafter subsequent to December 31, 2013 are as follows:
	2014	$	204,689
	2015		206,250
	2016		207,309
	2017		207,405
	2018		207,405
	Thereafter		1,469,119
	Total	$	2,502,177

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Long-term Purchase Commitment [Table Text Block]	'
	In order to maintain its exclusivity, the Company must purchase the following minimum amounts, in Euros, of the products for the indicated calendar year:
	Calendar Year	Minimum Annual Purchase Amount
	2014	500,000 Euros
	2015	1,000,000 Euros
	2016	2,500,000 Euros
	2017	4,000,000 Euros

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders Equity Note [Abstract]	'
Schedule of Stockholders Equity Note, Warrants or Rights [Table Text Block]	'
	The following table summarizes the common stock and warrant offerings during the years ended December 31, 2013 and 2012:
												Five-Year Warrants
										Common		Investor		Placement Agent
	Issuance			Gross			Issuance			Stock		Warrants		Warrants		Exercise
	Date			Proceeds			Costs			(Shares)		(Shares)		(Shares)		Price
	2/16/12			$	1,050,000		$	62,975		480,000		240,000		25,360		$	3.02
	8/14/12	[1]			265,000			-		121,143		60,571		-		$	2.19
	9/28/12	[2]			25,000			-		11,429		5,714		-		$	2.19
	10/11/12	[2]			5,000			-		2,286		1,143		-		$	2.19
	11/8/12	[3]			815,000	[4]		24,500		372,572		372,572	[5]	8,000	[5]	$	2.19
	2012 Total				2,160,000			87,475		987,430		680,000		33,360
	2/22/13				380,500			-		107,372		107,372		-		$	4.24
	4/11/13				236,000			37,100		66,596		66,596		6,660		$	4.24
	4/22/13				576,000			55,100		162,540		162,540		13,150		$	4.24
	5/31/13				288,000			31,300		81,270		81,270		8,127		$	4.24
	6/28/13				1,976,925			62,632		557,862		557,862		17,674		$	4.24
	11/14/13				6,000,000	[6]		-		1,672,474		836,237		-		$	5.69
	11/18/13				7,000,000			494,000		1,951,220		975,610		136,490		$	5.69
	2013 Total				16,457,425			680,132		4,599,334		2,787,487		182,101
	Total			$	18,617,425		$	767,607		5,586,764		3,467,487		215,461
		[1]	Includes 86,857 shares of common stock and five-year warrants to purchase 43,429 shares of common stock at an exercise price of $2.19 per share issued to certain officers and members of the Board of Directors in exchange for gross proceeds of $190,000.
		[2]	Issued to a member of the Board of Directors.
		[3]	Includes 89,143 shares of common stock and five-year warrants to purchase 89,143 shares of common stock at an exercise price of $2.19 per share issued to certain members of the Board of Directors for gross proceeds of $195,000.
		[4]	Includes $50,000 represented by the conversion of debt.
		[5]	See Note 15 – Fair Value Measurement for details regarding the fair value of the warrant liability recorded in connection with these issued warrants.
		[6]	See Note 9 – Commitment and Contingencies for details regarding the Celgene License, Marketing, and Development Agreement and Supply Agreement.
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	The following table summarizes stock-based compensation expense, which is reflected as selling, general and administrative expenses in the consolidated statements of operations:
			For The Years Ended
			December 31,
			2013			2012
	Options		$	3,948,025		$	1,421,338
	Warrants			172,913			3,777
	Restricted Stock Units			83,836			-
	Restricted Stock			1,309,087			550,000
	Total Stock-Based Compensation		$	5,513,861		$	1,975,115
Nonvested Restricted Stock Shares Activity [Table Text Block]	'
	The following table summarizes the restricted stock issued as compensation during the years ended December 31, 2013 and 2012:
	Issuance		Grantee		Shares		Vesting			Grant Date
	Date		Type		Issued		Term			Value
	1/11/12		Vendor		45,714		Immediate		$	100,000	[1]
	6/30/12		Officer		22,857		Immediate			100,000
	6/30/12		Officer		32,653		Immediate			100,000
	8/15/12		Consultant		2,286		Immediate			10,000
	9/20/12		Consultant		2,286		Immediate			10,000
	11/14/12		Consultant		4,571		Immediate			20,000
	11/14/12		Consultant		45,714		Immediate			200,000
	11/30/12		Consultant		2,286		Immediate			10,000
			Restricted Stock - Total		158,367					550,000
	11/8/12		Officer		70,753		[2]			154,773
			Restricted Stock Units - Total		70,753					154,773
			2012 - Total		229,120					704,773
	5/24/13		Consultant		2,286		Immediate			7,000
	6/28/13		Fmr. Officer		186,165		Immediate			570,130
	7/1/13		Consultant		16,429		Immediate			50,312
	10/15/13		Consultant		3,265		Immediate			10,000
	11/11/13		Fmr. Officer		186,165		Immediate			651,578
	11/14/13		Consultant		2,875		Immediate			10,063
	12/12/13		Employee		21,614		One year			150,001	[3]
	12/24/13		Consultant		1,409		Immediate			10,004
			Restricted Stock - Total		420,208					1,459,088
			2013 - Total		420,208				$	1,459,088
		[1]	See Note 13 –Related Party Transactions for additional details.
		[2]	Vests over three years and is subject to the Company’s achievement of certain market capitalization targets.  During the fourth quarter of 2013, 35,377 shares vested as a performance condition was met.
		[3]	Shares forfeited during 2013. The Company did not record any stock-based compensation expense during 2013 related to the issuance.
Schedule of Share-based Payment Award, Warrants, Valuation Assumptions [Table Text Block]	'
	In applying the Black-Scholes option pricing model to compensatory warrants issued, the Company used the following weighted average assumptions:
			For The Year Ended
			December 31,
			2013		2012
	Risk free interest rate		1.27	%	0.74	%
	Expected term (years)		5		5
	Expected volatility		99.59	%	98.49	%
	Expected dividends		0	%	0	%
Schedule of Share-based Compensation, Warrants, Activity [Table Text Block]	'
	A summary of the warrant activity, including common stock purchase warrants, during the years ended December 31, 2013 and 2012 is presented below:
								Weighted
					Weighted			Average
					Average			Remaining
			Number of		Exercise			Life		Intrinsic
			Warrants		Price			In Years		Value
	Outstanding, December 31, 2011		310,107		$	10.94
	Issued		715,647			2.63
	Anti-Dilutive Adjustment		539			51.19
	Exercised		-			-
	Forfeited		-22,085			51.19
	Outstanding, December 31, 2012		1,004,208		$	3.94
	Issued		3,189,778			5.15
	Exercised		-371,429			1.01
	Forfeited		-			-
	Outstanding, December 31, 2013		3,822,557		$	5.12		4.4		$	8,369,579
	Exercisable, December 31, 2013		3,756,558		$	5.12		4.4		$	8,207,235
Schedule of Warrants by Exercise Price Range [Table Text Block]	'
	The following table presents information related to warrants at December 31, 2013:
	Warrants Outstanding					Warrants Exercisable
						Weighted
				Outstanding		Average		Exercisable
	Exercise			Number of		Remaining Life		Number of
	Price			Warrants		In Years		Warrants
	$	2.19		202,286		3.8		202,286
		3.02		139,648		3.1		139,648
		3.5		2,286		3.3		2,286
		4.24		1,021,251		4.4		1,021,251
		4.38		188,444		4.8		143,112
		4.81		8,889		4.8		8,889
		5.69		1,971,194		4.9		1,950,527
		7		140,708		1.4		140,708
		8.75		147,851		1.4		147,851
				3,822,557		4.4		3,756,558

Stock_Options_Tables

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	'
	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:
			For The Years Ended
			December 31,
			2013		2012
	Risk free interest rate		1.4	%	0.75	%
	Expected term (years)		5.55		5.49
	Expected volatility		99.78	%	97.87	%
	Expected dividends		0	%	0	%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of the stock option activity during the years ended December 31, 2013 and 2012 is presented below:
							Weighted
					Weighted		Average
					Average		Remaining
			Number of		Exercise		Life	Intrinsic
			Options		Price		In Years	Value
	Outstanding, December 31, 2011		431,314		$	7
	Granted		1,979,576			6.13
	Exercised		-			-
	Forfeited		-77,068			4.81
	Outstanding, December 31, 2012		2,333,822		$	6.56
	Granted		3,319,421			6.37
	Exercised		-			-
	Forfeited		-667,657			6.96
	Outstanding, December 31, 2013		4,985,586		$	6.47	8.2	$	6,574,508
	Exercisable, December 31, 2013		2,381,469		$	5.87	6.9	$	4,241,527
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
	The following table presents information related to stock options at December 31, 2013:
	Options Outstanding					Options Exercisable
						Weighted
				Outstanding		Average	Exercisable
		Exercise		Number of		Remaining Life	Number of
	Price			Options		In Years	Options
	$	3.28		279,227		9.1	279,227
		3.5		117,125		-	-
		3.94		7,619		9.9	7,619
		4.38		1,233,854		6.4	853,325
		5.47		120,569		9.4	30,971
		5.69		114,286		4.9	114,286
		5.91		17,142		7	17,142
		6.34		280,342		5.9	280,342
		6.56		657,634		5	205,599
		6.82		780,535		10	12,500
		8.75		999,349		8.7	453,828
		9.19		114,285		4.9	114,285
		10.94		262,245		9.4	10,971
		11.38		1,145		4.7	1,145
		26.69		229		4.4	229
				4,985,586		6.9	2,381,469

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
	The income tax provision (benefit) consists of the following:
		For The Years Ended
		December 31,
		2013		2012
	Federal:
	Current	$	-	$	-
	Deferred		-6,528,000		-1,648,000
	State and local:
	Current		-		-
	Deferred		-1,140,000		-139,000
			-7,668,000		-1,787,000
	Change in valuation allowance		7,677,000		1,798,000
	Income tax provision (benefit)	$	9,000	$	11,000
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	The expected tax expense (benefit) based on the statutory rate reconciled with the actual expense (benefit) is as follows:
		For The Years Ended
		December 31,
		2013		2012
	US federal statutory rate	-34	%	-34	%
	State tax rate, net of federal benefit	-5.9	%	-5.9	%
	Permanent differences
	- Exercised warrant liability	3.3	%	0	%
	- Other	1.7	%	3.4	%
	Change in valuation allowance	34.9	%	36.7	%
	Income tax provision (benefit)	0	%	0.2	%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	Deferred tax assets consisted of the effects of temporary differences attributable to the following:
		As of December 31,
		2013		2012
	Deferred tax assets:
	Net operating loss carryforwards	$	10,703,000	$	7,940,000
	Stock-based compensation		2,825,000		1,469,000
	Intangible assets		4,059,000		870,000
	Accruals		326,000		-
	Other		230,000		196,000
	Total deferred tax assets		18,143,000		10,475,000
	Valuation allowance		-17,607,000		-9,930,000
	Deferred tax assets, net of valuation allowance		536,000		545,000
	Deferred tax liabilities:
	Property and equipment		-536,000		-545,000
	Goodwill		-53,000		-44,000
	Total deferred tax liabilities		-589,000		-589,000
	Net deferred tax liabilities	$	-53,000	$	-44,000

Concentration_of_Risk_Tables

Concentration of Risk (Tables)	12 Months Ended
	Dec. 31, 2013
Risks and Uncertainties [Abstract]	'
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	'
	Revenues and accounts receivable from our largest customers for the years ended December 31 were as follows:
		2013				2012
	Customer	% of Total Revenue		Accounts Receivable		% of Total Revenue		Accounts Receivable
	A	51	%	51	%	60	%	38	%
	B	16	%	0	%	16	%	39	%

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis:
		December 31,
		2013			2012
	Beginning balance as of January 1,	$	605,737		$	-
	Aggregate value of warrants issued		-			605,737
	Change in fair value of warrant liability		1,833,498			-
	Value of warrants exercised		-1,505,770			-
	Ending balance as of December 31,	$	933,465		$	605,737
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
	Assets and liabilities measured at fair value on a recurring or nonrecurring basis are as follows:
		Level		Level		Level
		1		2		3
	31-Dec-12
	Recurring:
	Warrant liabilities	N/A		N/A		$	605,737
	31-Dec-13
	Recurring:
	Warrant liabilities	N/A		N/A		$	933,465

Description_of_Business_and_Ba1

Description of Business and Basis of Presentation (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
Stockholders Equity, Reverse Stock Split	'1-for-43.75 reverse stock split	'	'
Common Stock, Par or Stated Value Per Share	$0.00	$0.00	$0.00

Liquidity_Details_Textual

Liquidity (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Liquidity Disclosures [Line Items]	'	'
Proceeds from Issuance of Common Stock	$15,797,293	$2,002,525
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants, Total	930,000	0
Common Stock [Member]	'	'
Liquidity Disclosures [Line Items]	'	'
Proceeds from Issuance of Common Stock	$16,457,425	$2,160,000
Development Stage Entities, Stock Issued, Shares, Issued for Cash	4,599,334	'
Stock and Warrants Issued During Period, Shares, Preferred Stock and Warrants	0	'
Preferred Stock [Member]	'	'
Liquidity Disclosures [Line Items]	'	'
Stock and Warrants Issued During Period, Shares, Preferred Stock and Warrants	250,000	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	8,843,519	3,408,783
Restricted Stock Units (RSUs) [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	35,376	70,753
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,822,557	1,004,208
Employee Stock Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,985,586	2,333,822

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Summary Of Significant Account Policies [Line Items]	'	'
Inventory Valuation Reserves	$76,580	$17,650
Goodwill	425,969	425,969
Research and Development Expense, Total	63,204	233,819
Advertising Expense	298,859	139,024
Shipping, Handling and Transportation Costs	$23,523	$14,635

Inventory_Details

Inventory (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventories [Line Items]	'	'
Raw materials	$174,176	$209,820
Work in process	57,030	25,119
Finished goods	346,843	102,037
Less: Inventory reserve	-76,580	-17,650
Total	$501,469	$319,326

Improvements_and_Equipment_net2

Improvements and Equipment, net (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
			Machinery and Equipment [Member]	Office Equipment [Member]	Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Machinery and equipment	$2,869,453	$2,869,453	'	'	'
Office furniture and equipment	44,844	40,124	'	'	'
Leasehold improvements	228,021	108,139	'	'	'
Property, Plant and Equipment, Gross, Total	3,142,318	3,017,716	'	'	'
Less: Accumulated depreciation and amortization	-1,397,070	-1,102,537	'	'	'
Improvements and equipment, net	$1,745,248	$1,915,179	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'10 years	'10 years	'	[1]
[1]	Leasehold improvements are amortized over the shorter of the remaining lease term or estimated useful life.

Improvements_and_Equipment_net3

Improvements and Equipment, net (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Depreciation, Depletion and Amortization, Total	$303,535	$297,818

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accrued Liabilities Current Line Items [Line Items]	'	'
Salaries, benefits and incentive compensation	$1,036,771	$230,281
Professional fees	83,317	11,736
Inventory	127,786	0
Other	20,025	7,711
Total accrued expenses	$1,267,899	$249,728

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Amount	$12,100,000	$11,700,000
Accumulated Amortization	-1,741,523	-1,370,833
Impairment	-8,100,000	0
Net	2,258,477	10,329,167
In Process Research and Development [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Amount	8,100,000	8,100,000
Accumulated Amortization	0	0
Impairment	-8,100,000	0
Net	0	8,100,000
Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated Useful Lives	'10 years	'10 years
Gross Amount	3,000,000	3,000,000
Accumulated Amortization	-1,475,000	-1,175,000
Impairment	0	0
Net	1,525,000	1,825,000
Customer Relationships [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated Useful Lives	'12 years	'12 years
Gross Amount	600,000	600,000
Accumulated Amortization	-245,834	-195,833
Impairment	0	0
Net	354,166	404,167
Distribution Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated Useful Lives	'5 years 3 months 7 days	'
Gross Amount	400,000	'
Accumulated Amortization	-20,689	'
Impairment	0	'
Net	$379,311	'

Intangible_AssetsDetails1

Intangible Assets(Details1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
2014	$426,190	'
2015	426,190	'
2016	426,190	'
2017	426,190	'
2018	424,548	'
Thereafter	129,169	'
Total	$2,258,477	$10,329,167

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization of Intangible Assets	$370,690	$350,000

Operating_Leases_Details

Operating Leases (Details) (USD $)	Dec. 31, 2013
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]	'
2014	$204,689
2015	206,250
2016	207,309
2017	207,405
2018	207,405
Thereafter	1,469,119
Total	$2,502,177

Operating_Leases_Details_Textu

Operating Leases (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Operating Leases [Line Items]	'	'
Stock Issued During Period Value Issued For Services1	$1,221,708	$300,000
Operating facilities, Langhorne [Member]	'	'
Operating Leases [Line Items]	'	'
Lease Expiration Date	31-Jan-26	'
Lease Incentive, Payable	100,745	'
Operating Leases, Rent Expense	204,930	191,597
Corporate office space, New York [Member]	'	'
Operating Leases [Line Items]	'	'
Stock Issued During Period Shares Issued For Services1	'	45,714
Stock Issued During Period Value Issued For Services1	'	100,000
Operating Leases, Rent Expense, fair value	32,000	'
Operating Leases, Rent Expense	'	$86,000

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (EUR €)	Dec. 31, 2013
Commitments And Contingencies [Line Items]	'
2014	€ 500,000
2015	1,000,000
2016	2,500,000
2017	€ 4,000,000

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2014

Jan. 25, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Common Stock [Member]

Common Stock [Member]

Issuance Date - November 18, 2013 [Member]

Issuance Date - November 18, 2013 [Member]

Placement Agent [Member]

Placement Agent [Member]

Placement Agent [Member]

Alliqua Biomedical Subsidiary [Member]

Alliqua Biomedical Subsidiary [Member]

Carolon Company [Member]

Noble Fiber Technologies License Agreement [Member]

Royalty Agreements [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Executive Employment Agreement One [Member]

Executive Employment Agreement One [Member]

Executive Employment Agreement Two [Member]

Executive Employment Agreement Two [Member]

Executive Employment Agreement Two [Member]

Executive Employment Agreement Two [Member]

Executive Employment Agreement Five [Member]

Executive Employment Agreement Five [Member]

Executive Employment Agreement Five [Member]

Executive Employment Agreement Five [Member]

Executive Employment Agreements [Member]

Consulting Agreements [Member]

Consulting Agreements [Member]

Sorbion Distributor Agreement [Member]

Common Stock [Member]

Issuance Date - November 18, 2013 [Member]

Sorbion Sachet [Member]

Sorbion Sachet [Member]

Former President [Member]

Former Executive Chairman [Member]

HepaLife Technologies Inc 2001 Incentive Stock Option Plan [Member]

Alliqua Inc 2011 Long Term Incentive Plan [Member]

Two Thousand Eleven Plan [Member]

Commitments And Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other Commitments, Future Minimum Payments, Remainder of Fiscal Year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$200,000

'

$200,000

'

'

'

'

'

'

'

'

'

'

Other Commitment, Due in Next Twelve Months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

225,000

'

225,000

'

'

'

'

'

'

'

'

'

'

Other Commitment, Due in Second Year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

'

250,000

'

'

'

'

'

'

'

'

'

'

Options To Purchase Of Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

125,714

'

125,714

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8.75

'

$8.75

'

'

$4.38

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

68,571

'

68,571

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued for Services

'

'

26,264

57,143

'

'

'

'

'

'

'

'

'

'

'

'

186,165

'

186,165

'

'

'

'

'

'

'

'

'

'

'

Professional Fees Monthly Payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500

'

2,500

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

114,286

'

'

'

'

'

'

'

Employee Benefits Stipend Amount Per Month

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

22,857

22,857

11,429

'

'

'

'

Upfront License Fees

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty Fee Percentage

'

'

'

'

'

'

'

'

'

'

'

'

9.75%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contractual Obligation, Due in Next Twelve Months

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contractual Obligation, Due in Second Year

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contractual Obligation, Due in Third Year

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contractual Obligation, Due in Fourth Year

'

'

'

'

'

'

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty Expense

'

'

'

'

'

'

'

'

'

200,000

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

4,599,334

987,429

'

1,672,474

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Issued During Period, Warrants, New Issues

'

'

'

'

'

'

182,101

33,360

836,237

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

'

'

'

5.69

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Common Stock

15,797,293

2,002,525

16,457,425

2,160,000

6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Granted, Value, Share-based Compensation, Net of Forfeitures, Total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

570,130

651,578

'

'

'

'

'

'

'

'

Operating Expenses, Total

19,833,202

4,288,192

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,963,114

292,305

'

Accounts Payable, Current

746,609

572,635

'

'

'

'

'

'

'

'

'

'

'

192,987

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contractual Obligation, Total

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum Sales Commitment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Upfront Fee

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Distribution Rights Payable

333,333

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Remaining Amortization Period

'

'

'

'

'

'

'

'

'

'

'

'63 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense

5,513,861

1,975,115

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,309,087

550,000

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

Co-operative and License Agreements, License Term

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Co-operative and License Agreements, License Renewal Period

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Recorded Unconditional Purchase Obligation, Due in Next Rolling Twelve Months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

689,000

Recorded Unconditional Purchase Obligation, Due in Rolling Year Two

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,378,000

Recorded Unconditional Purchase Obligation, Due in Rolling Year Three

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,444,000

Recorded Unconditional Purchase Obligation, Due in Rolling Year Four

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,510,000

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012
Gross Proceeds	$15,797,293		$2,002,525
Issuance Costs	680,132		87,475
Common Stock [Member]	'		'
Gross Proceeds	16,457,425		2,160,000
Issuance Costs	680,132		87,475
Common Stock	4,599,334		987,429
Common Stock and Warrant Offerings Total [Member]	'		'
Gross Proceeds	18,617,425		'
Issuance Costs	767,607		'
Common Stock	5,586,764		'
Investor [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	2,787,487		680,000
Investor [Member] | Common Stock and Warrant Offerings Total [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	3,467,487		'
Placement Agent [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	182,101		33,360
Exercise Price Of Warrants	$4.38		'
Placement Agent [Member] | Common Stock and Warrant Offerings Total [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	215,461		'
Issuance Date - February 22, 2013 [Member] | Common Stock [Member]	'		'
Gross Proceeds	380,500		'
Issuance Costs	0		'
Common Stock	107,372		'
Issuance Date - February 22, 2013 [Member] | Investor [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	107,372		'
Issuance Date - February 22, 2013 [Member] | Placement Agent [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	0		'
Exercise Price Of Warrants	$4.24		'
Issuance Date - April 11, 2013 [Member] | Common Stock [Member]	'		'
Gross Proceeds	236,000		'
Issuance Costs	37,100		'
Common Stock	66,596		'
Issuance Date - April 11, 2013 [Member] | Investor [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	66,596		'
Issuance Date - April 11, 2013 [Member] | Placement Agent [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	6,660		'
Exercise Price Of Warrants	$4.24		'
Issuance Date - April 22, 2013 [Member] | Common Stock [Member]	'		'
Gross Proceeds	576,000		'
Issuance Costs	55,100		'
Common Stock	162,540		'
Issuance Date - April 22, 2013 [Member] | Investor [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	162,540		'
Issuance Date - April 22, 2013 [Member] | Placement Agent [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	13,150		'
Exercise Price Of Warrants	$4.24		'
Issuance Date - May 31, 2013 [Member] | Common Stock [Member]	'		'
Gross Proceeds	288,000		'
Issuance Costs	31,300		'
Common Stock	81,270		'
Issuance Date - May 31, 2013 [Member] | Investor [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	81,270		'
Issuance Date - May 31, 2013 [Member] | Placement Agent [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	8,127		'
Exercise Price Of Warrants	$4.24		'
Issuance Date - June 28, 2013 [Member] | Common Stock [Member]	'		'
Gross Proceeds	1,976,925		'
Issuance Costs	62,632		'
Common Stock	557,862		'
Issuance Date - June 28, 2013 [Member] | Investor [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	557,862		'
Issuance Date - June 28, 2013 [Member] | Placement Agent [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	17,674		'
Exercise Price Of Warrants	$4.24		'
Issuance Date - November 14, 2013 [Member] | Common Stock [Member]	'		'
Gross Proceeds	6,000,000	[1]	'
Issuance Costs	0		'
Common Stock	1,672,474		'
Issuance Date - November 14, 2013 [Member] | Investor [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	836,237		'
Issuance Date - November 14, 2013 [Member] | Placement Agent [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	0		'
Exercise Price Of Warrants	$5.69		'
Issuance Date - November 18, 2013 [Member] | Common Stock [Member]	'		'
Gross Proceeds	7,000,000		'
Issuance Costs	494,000		'
Common Stock	1,951,220		'
Issuance Date - November 18, 2013 [Member] | Investor [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	975,610		'
Issuance Date - November 18, 2013 [Member] | Placement Agent [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	136,490		'
Exercise Price Of Warrants	$5.69		'
Issuance Date - February 16, 2012 [Member] | Common Stock [Member]	'		'
Gross Proceeds	'		1,050,000
Issuance Costs	'		62,975
Common Stock	'		480,000
Issuance Date - February 16, 2012 [Member] | Investor [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	'		240,000
Issuance Date - February 16, 2012 [Member] | Placement Agent [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	'		25,360
Exercise Price Of Warrants	'		$3.02
Issuance Date - August 14, 2012 [Member] | Common Stock [Member]	'		'
Gross Proceeds	'		265,000	[2]
Issuance Costs	'		0	[2]
Common Stock	'		121,143	[2]
Issuance Date - August 14, 2012 [Member] | Investor [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	'		60,571	[2]
Issuance Date - August 14, 2012 [Member] | Placement Agent [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	'		0	[2]
Exercise Price Of Warrants	'		$2.19	[2]
Issuance Date - September 28, 2012 [Member] | Common Stock [Member]	'		'
Gross Proceeds	'		25,000	[3]
Issuance Costs	'		0	[3]
Common Stock	'		11,429	[3]
Issuance Date - September 28, 2012 [Member] | Investor [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	'		5,714	[3]
Issuance Date - September 28, 2012 [Member] | Placement Agent [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	'		0	[3]
Exercise Price Of Warrants	'		$2.19	[3]
Issuance Date - October 11, 2012 [Member] | Common Stock [Member]	'		'
Gross Proceeds	'		5,000	[3]
Issuance Costs	'		0	[3]
Common Stock	'		2,286	[3]
Issuance Date - October 11, 2012 [Member] | Investor [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	'		1,143	[3]
Issuance Date - October 11, 2012 [Member] | Placement Agent [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	'		0	[3]
Exercise Price Of Warrants	'		$2.19	[3]
Issuance Date - November 08, 2012 [Member] | Common Stock [Member]	'		'
Gross Proceeds	'		815,000	[4],[5]
Issuance Costs	'		$24,500	[4]
Common Stock	'		372,572	[4]
Issuance Date - November 08, 2012 [Member] | Investor [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	'		372,572	[4],[6]
Issuance Date - November 08, 2012 [Member] | Placement Agent [Member]	'		'
Warrants Issued During Period, Warrants, New Issues	'		8,000	[4],[6]
Exercise Price Of Warrants	'		$2.19	[4]
[1]	See Note 9 B Commitment and Contingencies for details regarding the Celgene License, Marketing, and Development Agreement and Supply Agreement.
[2]	Includes 86,857 shares of common stock and five-year warrants to purchase 43,429 shares of common stock at an exercise price of $2.19 per share issued to certain officers and members of the Board of Directors in exchange for gross proceeds of $190,000.
[3]	Issued to a member of the Board of Directors.
[4]	Includes 89,143 shares of common stock and five-year warrants to purchase 89,143 shares of common stock at an exercise price of $2.19 per share issued to certain members of the Board of Directors for gross proceeds of $195,000.
[5]	Includes $50,000 represented by the conversion of debt.
[6]	See Note 15 B Fair Value Measurement for details regarding the fair value of the warrant liability recorded in connection with these issued warrants.

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Allocated Share-based Compensation Expense	$5,513,861	$1,975,115
Share Based Compensation Plan [Member]	'	'
Allocated Share-based Compensation Expense	5,513,861	1,975,115
Share Based Compensation Plan [Member] | Restricted Stock Units (RSUs) [Member]	'	'
Allocated Share-based Compensation Expense	83,836	0
Share Based Compensation Plan [Member] | Restricted Stock [Member]	'	'
Allocated Share-based Compensation Expense	1,309,087	550,000
Share Based Compensation Plan [Member] | Warrant [Member]	'	'
Allocated Share-based Compensation Expense	172,913	3,777
Share Based Compensation Plan [Member] | Employee Stock Option [Member]	'	'
Allocated Share-based Compensation Expense	$3,948,025	$1,421,338

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012
Vesting Term	'3		'3
Grant Date Value	$9,375,010		$3,056,383
Restricted Stock [Member]	'		'
Shares Isued	420,208		158,367
Grant Date Value	1,459,088		550,000
Restricted Stock Units (RSUs) [Member]	'		'
Shares Isued	'		70,753
Grant Date Value	'		154,773
Restricted Stock Total [Member]	'		'
Shares Isued	420,208		229,120
Grant Date Value	1,459,088		704,773
Consultant Two [Member] | Restricted Stock [Member]	'		'
Issuance Date	1-Jul-13		20-Sep-12
Shares Isued	16,429		2,286
Vesting Term	'Immediate		'Immediate
Grant Date Value	50,312		10,000
Consultant Three [Member] | Restricted Stock [Member]	'		'
Issuance Date	15-Oct-13		14-Nov-12
Shares Isued	3,265		4,571
Vesting Term	'Immediate		'Immediate
Grant Date Value	10,000		20,000
Consultant One [Member] | Restricted Stock [Member]	'		'
Issuance Date	24-May-13		15-Aug-12
Shares Isued	2,286		2,286
Vesting Term	'Immediate		'Immediate
Grant Date Value	7,000		10,000
Consultant Four [Member] | Restricted Stock [Member]	'		'
Issuance Date	14-Nov-13		14-Nov-12
Shares Isued	2,875		45,714
Vesting Term	'Immediate		'Immediate
Grant Date Value	10,063		200,000
Consultant Five [Member] | Restricted Stock [Member]	'		'
Issuance Date	24-Dec-13		30-Nov-12
Shares Isued	1,409		2,286
Vesting Term	'Immediate		'Immediate
Grant Date Value	10,004		10,000
Vendor [Member] | Restricted Stock [Member]	'		'
Issuance Date	'		11-Jan-12
Shares Isued	'		45,714
Vesting Term	'		'Immediate
Grant Date Value	'		100,000	[1]
Officer One [Member] | Restricted Stock [Member]	'		'
Issuance Date	'		30-Jun-12
Shares Isued	'		22,857
Vesting Term	'		'Immediate
Grant Date Value	'		100,000
Officer Two [Member] | Restricted Stock [Member]	'		'
Issuance Date	'		30-Jun-12
Shares Isued	'		32,653
Vesting Term	'		'Immediate
Grant Date Value	'		100,000
Officer Three [Member] | Restricted Stock Units (RSUs) [Member]	'		'
Issuance Date	'		8-Nov-12
Shares Isued	'		70,753	[2]
Grant Date Value	'		154,773
Former Officer One [Member] | Restricted Stock [Member]	'		'
Issuance Date	28-Jun-13		'
Shares Isued	186,165		'
Vesting Term	'Immediate		'
Grant Date Value	570,130		'
Former Officer Two [Member] | Restricted Stock [Member]	'		'
Issuance Date	11-Nov-13		'
Shares Isued	186,165		'
Vesting Term	'Immediate		'
Grant Date Value	651,578		'
Employee [Member] | Restricted Stock [Member]	'		'
Issuance Date	12-Dec-13		'
Shares Isued	21,614		'
Vesting Term	'One year		'
Grant Date Value	$150,001	[3]	'
[1]	See Note 13 BRelated Party Transactions for additional details.
[2]	Vests over three years and is subject to the Companybs achievement of certain market capitalization targets. During the fourth quarter of 2013, 35,377 shares vested as a performance condition was met.
[3]	Shares forfeited during 2013. The Company did not record any stock-based compensation expense during 2013 related to the issuance.

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3) (Warrant [Member])	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Warrant [Member]	'	'
Risk free interest rate	1.27%	0.74%
Expected term (years)	'5 years	'5 years
Expected volatility	99.59%	98.49%
Expected dividends	0.00%	0.00%

Stockholders_Equity_Details_4

Stockholders' Equity (Details 4) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Warrant [Member]	'	'
Number of Options Outstanding, December 31	1,004,208	310,107
Issued	3,189,778	715,647
Anti-Dilutive Adjustment	'	539
Exercised	-371,429	0
Forfeited	0	-22,085
Number of Options Outstanding, December 31	3,822,557	1,004,208
Number of Warrants, Exercisable Ending Balance	3,756,558	'
Weighted Average Exercise Price Outstanding, December 31	$3.94	$10.94
Issued	$5.15	$2.63
Anti-Dilutive Adjustment	'	$51.19
Exercised	$1.01	$0
Forfeited	$0	$51.19
Weighted Average Exercise Price Outstanding, December 31	$5.12	$3.94
Weighted Average Exercise Price, Exercisable Ending Balance	$5.12	'
Weighted Average Remaining Life In Years, Outstanding	'4 years 4 months 24 days	'
Weighted Average Remaining Life In Years, Exercisable	'4 years 4 months 24 days	'
Intrinsic Value, Outstanding	$8,369,579	'
Intrinsic Value, Exercisable	$8,207,235	'

Stockholders_Equity_Details_5

Stockholders' Equity (Details 5) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2013
Warrants Outstanding, Number of Warrants	3,822,557
Warrants Exercisable, Weighted Average Remaining Life In Years	'4 years 4 months 24 days
Warrants Exercisable, Number of Warrants	3,756,558
Exercise Price Range, 2.19 [Member]	'
Warrants Outstanding, Exercise Price	2.19
Warrants Outstanding, Number of Warrants	202,286
Warrants Exercisable, Weighted Average Remaining Life In Years	'3 years 9 months 18 days
Warrants Exercisable, Number of Warrants	202,286
Exercise Price Range, 3.02 [Member]	'
Warrants Outstanding, Exercise Price	3.02
Warrants Outstanding, Number of Warrants	139,648
Warrants Exercisable, Weighted Average Remaining Life In Years	'3 years 1 month 6 days
Warrants Exercisable, Number of Warrants	139,648
Exercise Price Range, 3.50 [Member]	'
Warrants Outstanding, Exercise Price	3.5
Warrants Outstanding, Number of Warrants	2,286
Warrants Exercisable, Weighted Average Remaining Life In Years	'3 years 3 months 18 days
Warrants Exercisable, Number of Warrants	2,286
Exercise Price Range, 4.24 [Member]	'
Warrants Outstanding, Exercise Price	4.24
Warrants Outstanding, Number of Warrants	1,021,251
Warrants Exercisable, Weighted Average Remaining Life In Years	'4 years 4 months 24 days
Warrants Exercisable, Number of Warrants	1,021,251
Exercise Price Range, 4.38 [Member]	'
Warrants Outstanding, Exercise Price	4.38
Warrants Outstanding, Number of Warrants	188,444
Warrants Exercisable, Weighted Average Remaining Life In Years	'4 years 9 months 18 days
Warrants Exercisable, Number of Warrants	143,112
Exercise Price Range, 4.81 [Member]	'
Warrants Outstanding, Exercise Price	4.81
Warrants Outstanding, Number of Warrants	8,889
Warrants Exercisable, Weighted Average Remaining Life In Years	'4 years 9 months 18 days
Warrants Exercisable, Number of Warrants	8,889
Exercise Price Range, 5.69 [Member]	'
Warrants Outstanding, Exercise Price	5.69
Warrants Outstanding, Number of Warrants	1,971,194
Warrants Exercisable, Weighted Average Remaining Life In Years	'4 years 10 months 24 days
Warrants Exercisable, Number of Warrants	1,950,527
Exercise Price Range, 7.00 [Member]	'
Warrants Outstanding, Exercise Price	7
Warrants Outstanding, Number of Warrants	140,708
Warrants Exercisable, Weighted Average Remaining Life In Years	'1 year 4 months 24 days
Warrants Exercisable, Number of Warrants	140,708
Exercise Price Range, 8.75 [Member]	'
Warrants Outstanding, Exercise Price	8.75
Warrants Outstanding, Number of Warrants	147,851
Warrants Exercisable, Weighted Average Remaining Life In Years	'1 year 4 months 24 days
Warrants Exercisable, Number of Warrants	147,851

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)

3 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 25, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Apr. 10, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

issuance cost [Member]

issuance of equity instruments [Member]

3.02 Exercise Price [Member]

3.09 Exercise Price [Member]

Placement Agent [Member]

Placement Agent [Member]

Placement Agent [Member]

Investor [Member]

Officers and members of the Board of Directors [Member]

investment banking services [Member]

investment banking services [Member]

Consultants [Member]

Consultants [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Condition One [Member]

Condition Two [Member]

members of board of directors [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Warrant [Member]

Warrant [Member]

Warrant One [Member]

4.38 Warrant [Member]

4.81 Warrant [Member]

Maximum [Member]

Investor [Member]

Performance Condition Probable Of Being Achieved [Member]

Performance Condition ImProbable Of Being Achieved [Member]

Un recognized Stock Based Compensation Expense Related To Warrants

255,537

255,537

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized

1,000,000

1,000,000

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Par or Stated Value Per Share

$0.00

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized

45,714,286

45,714,286

45,714,286

11,428,571

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Issued

11,484,191

11,484,191

5,924,627

'

45,714,286

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Base Price Value Per Share

$3.54

$3.54

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par or Stated Value Per Share

$0.00

$0.00

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investor Right Termination Conditions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'the closing sales price of the common stock for thirty (30) consecutive trading days is at least 200% of the per share purchase price

'the product of (A) the volume weighted average price of the common stock on its principal market and (B) its corresponding daily trading volume, each as reported by Bloomberg L.P., equals or exceeds $50,000

'

'

'

'

'

'

'

Exercise Price Of Warrants

'

'

'

'

'

'

'

$3.02

$2.19

$4.38

'

$4.81

'

$2.19

'

$3.50

$4.38

$5.69

'

'

'

'

$2.19

'

'

'

$4.38

'

$2.19

Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Weighted Average Period For Amortization

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 months 24 days

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total

$6,609,208

$6,609,208

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$23,646

$38,693

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,640

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.42

$1.65

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

'

86,857

'

'

'

'

250,000

'

'

'

89,143

'

'

'

'

'

'

Warrants To Purchase Common Stock

'

228,572

'

'

'

'

'

'

'

8,889

'

8,889

'

43,429

1,143

2,286

68,571

'

'

126,984

'

'

89,143

'

'

'

6,857

'

152,000

Warrants, Expiry Term

'

'

'

'

'

'

'

'

'

'

'5 years

'5 years

'5 years

'5 years

'

'5 years

'5 years

'

'

'

'

'

'5 years

'

'

'

'

'

'

Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants, Total

'

930,000

0

'

'

'

'

'

'

'

'

'

'

190,000

'

'

'

'

'

1,000,000

'

'

195,000

'

'

'

'

'

'

Preferred Stock, Dividend Rate, Percentage

'

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.00%

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock Conversion Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.94

'

'

'

'

'

'

'

'

'

Professional Fees

'

'

'

'

'

'

'

'

'

70,000

'

'

'

'

6,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock Adjusted Conversion Price

$3.59

$3.59

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Shares Issued

'

279,505

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Amount Converted

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Dividend Rate, Per-Dollar-Amount

'

$2,724

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, issuance discount

'

573,188

'

'

'

113,906

459,282

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issuance Costs

'

70,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant Issuance Costs

'

43,906

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Adjustment of Warrants

'

'

'

'

'

'

240,507

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, initial Beneficial Conversion Feature, Value

'

'

'

'

'

'

129,396

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, contingent Beneficial Conversion Feature, Value

'

'

'

'

'

'

89,379

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Amount Issued

'

759,493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Convertible Preferred Stock

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liquidated Damages Payable, On Failure Of Delivery Of Shares

'

'

'the Company is required to (i) upon its failure to provide for the timely delivery of shares upon the exercise of the warrants, pay liquidated damages consisting of a cash payment of $10 per trading day (increasing to $20 per trading day on the fifth trading day) for each $1,000 of warrant shares until such certificates are delivered

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

35,377

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.50

'

'

Fair Value Assumptions, Expected Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

99.44%

'

'

Fair Value Assumptions, Expected Dividend Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.30%

'

'

Debt Conversion, Original Debt, Amount

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Beneficial Conversion Feature

'

978,268

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'

'1 year 7 months 6 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year 9 months 18 days

'

'

'

'

'

Warrants , Granted in period, Grant Date Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,777

168,255

'

'

'

'

'

'

'

'

'

'

'

'

Warrants , Vesting terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The warrants vest in twelve equal monthly installments from the date of issuance.

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Shares Warrants Exercised

'

261,030

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number Of Warrants To Purchase Common Stock Exercised

'

371,429

'

'

'

'

'

125,714

245,715

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercised, Intrinsic Value

'

$2,167,657

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock_Options_Details

Stock Options (Details) (Employee Stock Option [Member])	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Employee Stock Option [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk free interest rate	1.40%	0.75%
Expected term (years)	'5 years 6 months 18 days	'5 years 5 months 26 days
Expected volatility	99.78%	97.87%
Expected dividends	0.00%	0.00%

Stock_Options_Details_1

Stock Options (Details 1) (Employee Stock Option [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Employee Stock Option [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of Options Outstanding, December 31	2,333,822	431,314
Number of Options, Granted	3,319,421	1,979,576
Number of Options, Exercised	0	0
Number of Options, Forfeited	-667,657	-77,068
Number of Options Outstanding, December 31	4,985,586	2,333,822
Number of Options Outstanding, Exercisable December 31 2013	2,381,469	'
Weighted Average Exercise Price Outstanding, December 31	$6.56	$7
Weighted Average Exercise Price, Granted	$6.37	$6.13
Weighted Average Exercise Price, Exercised	$0	$0
Weighted Average Exercise Price, Forfeited	$6.96	$4.81
Weighted Average Exercise Price Outstanding, December 31	$6.47	$6.56
Weighted Average Exercise Price, Exercisable December 31, 2013	$5.87	'
Weighted Average Remaining Life In Years, Outstanding December 31, 2013	'8 years 2 months 12 days	'
Weighted Average Remaining Life In Years, Exercisable December 31, 2013	'6 years 10 months 24 days	'
Intrinsic Value, Outstanding December 31, 2013	$6,574,508	'
Intrinsic Value, Exercisable December 31, 2013	$4,241,527	'

Stock_Options_Details_2

Stock Options (Details 2) (Employee Stock Option [Member], USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Number of Options	4,985,586
Options Exercisable, Weighted Average Remaining Life In Years	'6 years 10 months 24 days
Options Exercisable, Number of Options	2,381,469
Exercise Price 3.28 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	3.28
Options Outstanding, Number of Options	279,227
Options Exercisable, Weighted Average Remaining Life In Years	'9 years 1 month 6 days
Options Exercisable, Number of Options	279,227
Exercise Price 3.50 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	3.5
Options Outstanding, Number of Options	117,125
Options Exercisable, Weighted Average Remaining Life In Years	'0 years
Options Exercisable, Number of Options	0
Exercise Price 3.94 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	3.94
Options Outstanding, Number of Options	7,619
Options Exercisable, Weighted Average Remaining Life In Years	'9 years 10 months 24 days
Options Exercisable, Number of Options	7,619
Exercise Price 4.38 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	4.38
Options Outstanding, Number of Options	1,233,854
Options Exercisable, Weighted Average Remaining Life In Years	'6 years 4 months 24 days
Options Exercisable, Number of Options	853,325
Exercise Price 5.47 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	5.47
Options Outstanding, Number of Options	120,569
Options Exercisable, Weighted Average Remaining Life In Years	'9 years 4 months 24 days
Options Exercisable, Number of Options	30,971
Exercise Price 5.69 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	5.69
Options Outstanding, Number of Options	114,286
Options Exercisable, Weighted Average Remaining Life In Years	'4 years 10 months 24 days
Options Exercisable, Number of Options	114,286
Exercise Price 5.91 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	5.91
Options Outstanding, Number of Options	17,142
Options Exercisable, Weighted Average Remaining Life In Years	'7 years
Options Exercisable, Number of Options	17,142
Exercise Price 6.34 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	6.34
Options Outstanding, Number of Options	280,342
Options Exercisable, Weighted Average Remaining Life In Years	'5 years 10 months 24 days
Options Exercisable, Number of Options	280,342
Exercise Price 6.56 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	6.56
Options Outstanding, Number of Options	657,634
Options Exercisable, Weighted Average Remaining Life In Years	'5 years
Options Exercisable, Number of Options	205,599
Exercise Price 6.82 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	6.82
Options Outstanding, Number of Options	780,535
Options Exercisable, Weighted Average Remaining Life In Years	'10 years
Options Exercisable, Number of Options	12,500
Exercise Price 8.75 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	8.75
Options Outstanding, Number of Options	999,349
Options Exercisable, Weighted Average Remaining Life In Years	'8 years 8 months 12 days
Options Exercisable, Number of Options	453,828
Exercise Price 9.19 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	9.19
Options Outstanding, Number of Options	114,285
Options Exercisable, Weighted Average Remaining Life In Years	'4 years 10 months 24 days
Options Exercisable, Number of Options	114,285
Exercise Price 10.94 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	10.94
Options Outstanding, Number of Options	262,245
Options Exercisable, Weighted Average Remaining Life In Years	'9 years 4 months 24 days
Options Exercisable, Number of Options	10,971
Exercise Price 11.38 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	11.38
Options Outstanding, Number of Options	1,145
Options Exercisable, Weighted Average Remaining Life In Years	'4 years 8 months 12 days
Options Exercisable, Number of Options	1,145
Exercise Price 26.69 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	26.69
Options Outstanding, Number of Options	229
Options Exercisable, Weighted Average Remaining Life In Years	'4 years 4 months 24 days
Options Exercisable, Number of Options	229

Stock_Options_Details_Textual

Stock Options (Details Textual) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	'	$2.80	$1.54
Allocated Share-based Compensation Expense	'	$5,513,861	$1,975,115
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	6,609,208	6,609,208	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'	'1 year 7 months 6 days	'
Allocated Share-based Compensation Expense, performance was not rendered	'	386,119	'
Proceeds From Issuance Of Common Stock And Warrants	'	25,495	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	'	'3	'3
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	'	9,375,010	3,056,383
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	35,377	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	'	$4.38	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	'	$8.75	'
2011 Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,828,571	1,828,571	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	3,319,421	1,979,576
Minimum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	'	$3.28	$4.38
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'5 years	'5 years
Maximum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	'	$10.94	$8.75
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'10 years	'10 years
Award Date May 17, 2012 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	'	530,286
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	'	'	914,080
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	'	'	79,543
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value	'	'	$4.38
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'10 years
Award Date May 17, 2012 [Member] | Minimum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	'	'	$4.38
Award Date May 17, 2012 [Member] | Maximum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	'	'	$6.56
Award Date November 27, 2012 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	'	457,143
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	'	'	695,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	'	'	57,143
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value	'	'	$8.75
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'10 years
Award Date November 5, 2012 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	'	'	$4.38
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	'	212,261
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	'	'	318,833
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'10 years
Award Date November 29, 2012 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	'	177,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	'	'	292,670
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	'	'	59,200
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value	'	'	$4.38
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'10 years
Award Date December 20, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$6.82	$6.82	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	730,535	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	'	3,826,039	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'10 years	'
Award Date July 22, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	622,170	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	'	1,556,984	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'9 years 6 months	'
Award Date February 4, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	'	$3.18	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	279,227	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	'	684,107	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'10 years	'
Award Date May 10, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	171,432	171,432	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	274,275	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	'	292,406	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	'	57,144	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'10 years	'
Award Date September 03, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	185,142	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	'	384,210	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	'	61,714	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value	'	$4.38	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'10 years	'
Reserved for Outstanding Options [Member] | 2011 Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	681,053	681,053	'
Reserved for Outstanding Options [Member] | Inactive Stock Option Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	352,191	352,191	'
Available for Future Option Issuances [Member] | 2011 Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,147,518	1,147,518	'
Reserved for non-plan outstanding options [Member] | Inactive Stock Option Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,952,342	3,952,342	'
Vesting Year One [Member] | Award Date November 27, 2012 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	'	'	$8.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	'	'	57,143
Vesting Year One [Member] | Award Date November 5, 2012 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	'	'	70,754
Vesting Year One [Member] | Award Date November 29, 2012 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	'	'	$6.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	'	'	59,200
Vesting Year One [Member] | Award Date December 20, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	81,171	81,171	'
Vesting Year One [Member] | Award Date May 10, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$4.38	$4.38	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	57,144	57,144	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	'	54,855	'
Vesting Year One [Member] | Award Date September 03, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$6.56	$6.56	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	61,714	61,714	'
Vesting Year Two [Member] | Award Date November 27, 2012 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	'	'	$8.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	'	'	57,143
Vesting Year Two [Member] | Award Date November 5, 2012 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	'	'	70,754
Vesting Year Two [Member] | Award Date November 29, 2012 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	'	'	$8.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	'	'	59,200
Vesting Year Two [Member] | Award Date May 10, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$5.47	$5.47	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	54,855	54,855	'
Vesting Year Two [Member] | Award Date September 03, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$8.75	$8.75	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	61,714	61,714	'
Vesting Year Three [Member] | Award Date November 27, 2012 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	'	'	$8.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	'	'	57,143
Vesting Year Three [Member] | Award Date November 5, 2012 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	'	'	70,753
Vesting Year Three [Member] | Award Date May 10, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$6.56	$6.56	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	54,855	54,855	'
Vesting in Next Eight Succeeding Quarterly Anniversaries [Member] | Award Date December 20, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	81,171	81,171	'
Vesting Year Four [Member] | Award Date May 10, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$8.75	$8.75	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	54,855	54,855	'
Vesting Year Five [Member] | Award Date May 10, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$10.94	$10.94	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	54,855	54,855	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	'	476,794	'
Vesting Option One [Member] | Award Date July 22, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	'	106,057	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$6.56	$6.56	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	207,290	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	'	$6.56	'
Vesting Option Two [Member] | Award Date July 22, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	'	114,286	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$8.75	$8.75	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	207,290	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	'	$8.75	'
Vesting Option Three [Member] | Award Date July 22, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	'	57,142	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$10.94	$10.94	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	207,290	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	'	$8.75	'
Non Employee Director [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	536,764	536,764	'
Improbable performace condition [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	137,332	137,332	'
Consultant [Member] | Award Date November 14, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$6.56	$6.56	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	80,000	80,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	160,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	'	371,992	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	'	80,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value	'	$5.69	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'5 years	'
Officer [Member] | Award Date November 14, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$3.50	$3.50	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	117,125	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	'	310,482	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'10 years	'
Officer [Member] | Vesting Year One [Member] | Award Date November 14, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	32,549	32,549	'
Officer [Member] | Vesting Year Two [Member] | Award Date November 14, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	41,116	41,116	'
Officer [Member] | Vesting Year Three [Member] | Award Date November 14, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	43,460	43,460	'
Performance Criteria Date, December 31, 2013 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Allocated Share-based Compensation Expense	'	$411,614	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Federal:	'	'
Current	$0	$0
Deferred	-6,528,000	-1,648,000
State and local:	'	'
Current	0	0
Deferred	-1,140,000	-139,000
Federal, State and Local Income Tax Expense Benefit, Continuing Operations	-7,668,000	-1,787,000
Change in valuation allowance	7,677,000	1,798,000
Income tax provision (benefit)	$9,000	$11,000

Income_Taxes_Details_1

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]	'	'
US federal statutory rate	-34.00%	-34.00%
State tax rate, net of federal benefit	-5.90%	-5.90%
Permanent differences	'	'
- Exercised warrant liability	3.30%	0.00%
- Other	1.70%	3.40%
Change in valuation allowance	34.90%	36.70%
Income tax provision (benefit)	0.00%	0.20%

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Net operating loss carryforwards	$10,703,000	$7,940,000
Stock-based compensation	2,825,000	1,469,000
Intangible assets	4,059,000	870,000
Accruals	326,000	0
Other	230,000	196,000
Total deferred tax assets	18,143,000	10,475,000
Valuation allowance	-17,607,000	-9,930,000
Deferred tax assets, net of valuation allowance	536,000	545,000
Deferred tax liabilities:	'	'
Property and equipment	-536,000	-545,000
Goodwill	-53,000	-44,000
Total deferred tax liabilities	-589,000	-589,000
Net deferred tax liabilities	($53,000)	($44,000)

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
		Domestic Tax Authority [Member]	State and Local Jurisdiction [Member]
Income Tax Disclosure [Line Items]	'	'	'
Operating Loss Carryforwards	'	$27,408,000	$20,468,000
Operating Loss Carryforwards, Expiration Year	'2018	'	'

Related_Party_Details_Textual

Related Party (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Related Party Transaction [Line Items]	'	'
Receipt of subscription receivable	$20,000	'
Warrants To Purchase Common Stock	228,572	'
Common Stock [Member]	'	'
Related Party Transaction [Line Items]	'	'
Stock Issued During Period, Shares, New Issues	4,599,334	987,429
Receipt of subscription receivable	0	'
Issuance Date - January 11, 2012 [Member] | Common Stock [Member]	'	'
Related Party Transaction [Line Items]	'	'
Stock Issued During Period, Shares, New Issues	'	45,714
Four Director And Affiliate Of Director [Member]	'	'
Related Party Transaction [Line Items]	'	'
Stock Issued During Period, Shares, New Issues	76,190	'
Warrants, Term	'5 years	'
Warrants To Purchase Common Stock	76,190	'
Exercise Price Of Warrants	$4.24	'
Proceeds From Issuance Of Common stock And Warrants	270,000	'
Five Director [Member]	'	'
Related Party Transaction [Line Items]	'	'
Stock Issued During Period, Shares, New Issues	231,393	'
Warrants, Term	'5 years	'
Warrants To Purchase Common Stock	231,393	'
Exercise Price Of Warrants	$4.24	'
Proceeds From Issuance Of Common stock And Warrants	$820,000	'

Concentration_of_Risk_Details

Concentration of Risk (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Sales Revenue, Net [Member] | Customer A [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	51.00%	60.00%
Sales Revenue, Net [Member] | Customer B [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	16.00%	16.00%
Accounts Receivable [Member] | Customer A [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	51.00%	38.00%
Accounts Receivable [Member] | Customer B [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	0.00%	39.00%

Concentration_of_Risk_Details_

Concentration of Risk (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Concentration Risk [Line Items]	'	'
Cost of Goods Sold, Direct Materials	$203,239	$124,552

Fair_Value_Measurement_Details

Fair Value Measurement (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning balance as of January 1,	$605,737	$0
Aggregate value of warrants issued	0	605,737
Change in fair value of warrant liability	1,833,498	0
Value of warrants exercised	-1,505,770	0
Ending balance as of December 31,	$933,465	$605,737

Fair_Value_Measurement_Details1

Fair Value Measurement (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Inputs, Level 1 [Member]	'	'
Recurring:	'	'
Warrant liabilities	'	'
Fair Value, Inputs, Level 2 [Member]	'	'
Recurring:	'	'
Warrant liabilities	'	'
Fair Value, Inputs, Level 3 [Member]	'	'
Recurring:	'	'
Warrant liabilities	$933,465	$605,737

Fair_Value_Measurement_Details2

Fair Value Measurement (Details Textual) (USD $)	11 Months Ended	12 Months Ended
	Dec. 02, 2013	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Warrants To Purchase Common Stock	'	228,572	'
Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss	'	1,141,964	'
Fair Value, Inputs, Level 3 [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Fair Value Assumptions, Expected Volatility Rate	99.44%	102.63%	97.26%
Fair Value Assumptions, Risk Free Interest Rate	1.01%	1.27%	0.65%
Fair Value Assumptions, Expected Term	'3 years 11 months 8 days	'3 years 10 months 10 days	'5 years
Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%

Defined_Contribution_Plan_Deta

Defined Contribution Plan (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Defined Benefit Plan Disclosure [Line Items]	'	'
Description of Defined Contribution Pension and Other Postretirement Plans	'Participants may contribute up to 100% of their total compensation to the Plan, not to exceed the limit as defined in the Code.	'
Defined Contribution Plan, Administrative Expenses	$0	$0

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (Subsequent Event [Member], USD $)	1 Months Ended			12 Months Ended	1 Months Ended
	Jan. 31, 2014	Jan. 31, 2014	Jan. 31, 2014	Dec. 31, 2013	Jan. 31, 2014	Jan. 31, 2014	Jan. 31, 2014
		Maximum [Member]	Minimum [Member]	Chief Executive Officer [Member]	President and Chief Executive Officer [Member]	Director One [Member]	Director Two [Member]
					2011 Long-Term Incentive Plan [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'	'
Stock Granted, Value, Share-based Compensation, Forfeited	$278,096	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value	'	$9.19	$6.34	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total	'	'	'	'	'	194,667	194,667
Stock Issued During Period, Shares, Restricted Stock Award, Gross	'	'	'	'	369,395	'	'
Payments for resignation	'	'	'	$210,000	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	'	'	'	'2 years	'	'	'